[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "response": "Unfortunately, the provided information does not clearly state any synonyms for Acrokeratosis paraneoplastica. Based on context clues, a reasonable synonym could potentially be \"Bazex's syndrome,\" as the document mentions reviewing literature about Bazex's syndrome in the context of Acrokeratosis paraneoplastica. However, without more definitive confirmation in the information provided, I do not want to presume that is an actual medical synonym. Let me know if you have any other details that could help determine or confirm synonyms for this medical term."
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "response": "Based on the information provided, there are some similarities and differences between Weaver syndrome and Sotos syndrome:\n\nSimilarities:\n- Both involve pre- and postnatal overgrowth\n- Both have accelerated bone maturation\n- Both have characteristic craniofacial features\n- Both involve developmental delay\n\nDifferences: \n- Weaver syndrome is generally a sporadic disorder, while Sotos has an autosomal dominant inheritance pattern in many cases. \n- The molecular basis is known for most cases of Sotos (NSD1 gene mutations/deletions) but is unknown for most cases of Weaver syndrome.  \n- Patients with Sotos have an estimated 2-3% risk of tumors, particularly leukemia and lymphoma. The document reports a 10.9% frequency of tumors/malignancies in Weaver syndrome, but this is likely an overestimate.  \n- This document reports the first case of an association between Weaver syndrome and acute lymphoblastic leukemia. It's unclear if this is an incidental finding or part of the syndrome.\n\nIn summary, the two syndromes have overlapping features but differ in their genetics and malignancy risk profiles. The potential link with ALL in Weaver syndrome needs further investigation."
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "response": "Based on the document, there have been multiple releases of the JASPAR database over time. Specifically:\n\n- The 2016 release expanded the JASPAR CORE collection with 494 new transcription factor (TF) binding profiles and updated 59 existing profiles. This was an 83% expansion and 10% update compared to the previous release.\n\n- The 2016 release also introduced 130 transcription factor flexible models trained on ChIP-seq data for vertebrates.\n\n- It introduced a new web tool to infer JASPAR TF binding profiles.\n\n- It provided a Ruby module to ease programmatic access to JASPAR profiles. \n\n- It released a JASPAR2016 R/Bioconductor data package with the data.\n\nThe document does not provide specific details on previous JASPAR releases or versions, just that the 2016 release represented major expansions and updates over the \"previous release\". So there is no additional chronological release information that can be extracted. But there have clearly been multiple releases with the 2016 version representing a major update."
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "response": "Unfortunately, the provided documents do not contain any information about the function of the KP4 protein. The documents discuss the K3 and K5 proteins, which are viral ubiquitin E3 ligases that downregulate MHC-I and other immunoreceptors. The documents also discuss the cellular protein PLP2, which was found to be essential for the activity of the K5 viral ligase. However, there is no mention of the KP4 protein or its function. Without any information provided on KP4, I do not have enough context to provide a reasonable answer or reply regarding its function. I would need additional information that specifically addresses the KP4 protein in order to respond about its functional role. Please let me know if you have any other documents or details on KP4 that could clarify its function."
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "response": "Based on the information provided, DITPA is indeed a thyroid hormone analog that has been utilized in experimental and clinical studies. Specifically:\n\n- DITPA is described as \"a thyroid hormone analog that is currently in phase II clinical trials.\" This indicates it has been used in clinical studies.\n\n- The document discusses a study comparing the effects of DITPA and L-thyroxine (T4) in normal and cardiomyopathic hamsters. This is an experimental study utilizing DITPA.\n\nSo in summary, yes, DITPA is a thyroid hormone analog that has been used both in experimental animal studies as well as human clinical trials, according to the information provided. The document summarizes an experimental study in hamsters evaluating its efficacy and comparing it to the thyroid hormone T4."
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "response": "Unfortunately I do not have enough context in the provided information to describe what the COUGER tool is. The article excerpt discusses maintaining dental instruments like tartar scrapers, curettes, excavators and elevators in an animal care practice by properly sharpening them. However, it does not mention anything about a tool called the COUGER. Without more details on what this tool is used for or what field it is related to, I cannot provide a description of it. I'd be happy to give more information if additional context about the COUGER tool is provided. Please let me know if you can clarify what specifically you'd like to know about it."
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "response": "Based on the document, there is no clear mention of any drugs specifically for treating Tick-borne Encephalitis. The document examines the clinical course, symptoms, and sequelae of Tick-borne Encephalitis in children, but does not discuss any drug treatments.\n\nSome key points from the document:\n\n- It evaluates the demographic, epidemiological data, symptoms, clinical course, and laboratory findings of 170 children with Tick-borne Encephalitis in the Czech Republic.\n\n- 58% of cases had a biphasic clinical course. Common symptoms included headache, fever, vomiting, and meningeal signs.  \n\n- Meningitis was more common (77%) than meningoencephalitis (13%). \n\n- 90% had inflammatory changes in the CSF (cerebrospinal fluid).\n\n- 99% had IgM antibodies against the Tick-borne Encephalitis virus in serum early in infection.\n\n- Only 1-2% had severe or mild/moderate permanent sequelae. \n\n- It concludes Tick-borne Encephalitis has a benign course in children with minimal sequelae.\n\nSo in summary, the document does not mention any specific drug treatments, but rather focuses on the symptoms and clinical outcome of the disease in children. Let me know if you need any clarification or have additional questions!"
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "response": "Based on the information provided, the UCSC Genome Browser Database contains genome sequence data and related annotations that can be visualized using the UCSC Genome Browser tool. However, there is no direct mention of a database specifically for DNA shape annotations. The document discusses genome sequence data and various types of annotations in the UCSC Genome Browser, but does not specify DNA shape annotations as one of the annotation types. So while the UCSC Genome Browser is a useful genome database and visualization tool, this passage does not indicate that it contains a database for DNA shape annotations. Additional information would be needed to determine if UCSC or another database hosts DNA shape annotation data."
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "response": "Based on the information provided, there is no clear evidence that mutations in the EZH2 gene are associated with specific syndromes. However, the passage does suggest some potential connections between EZH2 and certain conditions:\n\n1) EZH2 is proposed as a candidate gene for some characteristics of Down syndrome, since a pseudogene was previously mapped to chromosome 21. However, the functional EZH2 gene actually maps to chromosome 7.\n\n2) EZH2 may play a role in pathogenesis of myeloid leukemias involving abnormalities of chromosome region 7q35-q36. This is based on its mapping to this region and its nature as a Polycomb group protein involved in regulation of development.\n\n3) EZH2 has been shown to interact with proteins involved in mental retardation (XNP) and hematopoietic cell development (Vav). This suggests it could play a role in central nervous system and blood cell development.\n\nSo while no definitive syndromic associations are described, the passage points to connections between EZH2 mutations and possible developmental, neurological, or cancer phenotypes. Further research would be needed to clarify if specific syndromes are caused by or correlated with mutations in this gene. Let me know if you need any clarification or have additional questions!"
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "response": "Unfortunately the document provided does not contain a straightforward list of specific human proteins that undergo a dimer-to-tetramer transition. However, it provides some relevant information:\n\n- The document discusses experiments involving tetramers of glyceraldehydephosphate dehydrogenase (GAPDH) and lactate dehydrogenase (LDH). These are two human proteins capable of transitioning between dimer and tetramer states.\n\n- The exchange of subunits among undissociated GAPDH and LDH particles is discussed. This implies these proteins can exist as dimers or tetramers.\n\n- There is a comparison of the kinetics of subunit exchange for GAPDH/LDH tetramers versus simpler dimers. This suggests GAPDH and LDH are examples of human proteins that can undergo dimer-tetramer transitions.\n\nSo in summary, two human proteins mentioned that appear to be capable of dimer-tetramer transitions are:\n\n- Glyceraldehydephosphate dehydrogenase (GAPDH) \n- Lactate dehydrogenase (LDH)\n\nThe document does not provide an explicit list of such proteins, but focuses its discussion on GAPDH and LDH as examples."
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "response": "Unfortunately, the documents provided do not clearly mention which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein. The document discusses phospholamban (PLB) and its interaction with SERCA in regulating calcium ion transport in the sarcoplasmic reticulum of cardiac myocytes. However, it does not state that PLB interacts with another protein that is anti-apoptotic. More information would be needed to definitively answer which specific protein interacts with PLN and is anti-apoptotic. Based on the limited information provided, I do not have enough knowledge to reasonably identify such a protein. I apologize that I could not directly address the question asked with the details available. Please let me know if you have any other questions or need clarification."
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "response": "Yes, vitamin D supplementation has been shown to reduce the incidence of falls in older people in clinical trials. Specifically, several randomized, placebo-controlled clinical trials over the past 5 years have found that taking 400-1,200 IU per day of vitamin D along with 800-1,500 mg per day of calcium can reduce the risk of falls and fall-related fractures, especially in women over age 65 who have vitamin D deficiency (serum 25-hydroxyvitamin D levels < 50 nmol/L). A recently published meta-analysis of over 10,000 participants further supports this, with the highest level of evidence (Grade Ia according to the Oxford Centre for Evidence-Based Medicine) supporting vitamin D supplementation for the primary prevention of falls in the elderly. Therefore, multiple high-quality clinical trials provide strong evidence that vitamin D supplementation can help reduce falls in the senior population."
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "response": "Based on the information provided, it does appear that there is an association between Jarid2 and miR-155 in Th17 cells:\n\n1) The document states that miR-155-deficient Th17 cells express increased amounts of Jarid2. This suggests an inverse relationship between miR-155 levels and Jarid2 expression.\n\n2) Mir155 binding by Th17 cell transcription factors and high expression of miR-155 during Th17 cell differentiation implies that miR-155 normally acts to regulate gene expression in Th17 cells. \n\n3) The increased binding of PRC2 (which Jarid2 recruits) to chromatin in miR-155-deficient cells, along with the failure to express several Th17 cytokines, indicates that increased Jarid2/PRC2 activity suppresses aspects of the Th17 genetic program that are normally promoted by miR-155.\n\n4) Partial suppression of the defects seen in miR-155-deficient Th17 cells after deleting Jarid2 suggests miR-155 acts at least partly by inhibiting Jarid2 function in wild-type Th17 cells.\n\nIn summary, the evidence supports a regulatory connection where miR-155 acts to inhibit Jarid2 expression and repressive chromatin effects in Th17 cells, promoting aspects of Th17 cytokine expression. Loss of miR-155 leads to derepression of Jarid2 and related defects in the Th17 genetic program."
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "response": "Based on the information in the document, the human hoxD cluster contains 4-5 AbdB-related genes. Specifically, the document states:\n\n\"While the HOXA, HOXC and HOXD clusters contain four to five AbdB-related genes, only one gene (Hoxb-9) is found in the HOXB complex.\"\n\nThis indicates that the human hoxD cluster contains 4-5 AbdB-related genes. The document does not provide an exact number, but gives a range of 4-5 genes contained within the hoxD cluster."
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "response": "Based on the information provided, Casein Kinase 1 (CK1) recognizes phosphorylation motifs in target proteins. Some known consensus motifs for CK1 phosphorylation include:\n\n- S/T-X-X-S/T - Where S/T represents serine or threonine, and X refers to any amino acid. The serines/threonines are the phosphorylated residues. This is a classic CK1 motif.\n\n- pS/pT-X2-S/T - This motif refers to acidic residues (aspartic acid or glutamic acid) upstream of the phosphorylation site. The \"pS/pT\" indicates the presence of a previously phosphorylated serine or threonine residue.\n\n- D/E-X2-D/E-X-S/T - A CK1 motif containing two upstream acidic residues (aspartic acid or glutamic acid).\n\n- S/T-X1-2-D/E - Motif with a single upstream acidic residue.\n\nSo in summary, CK1 mainly recognizes Serine and Threonine residues within conserved acidic motifs containing negatively charged residues like Aspartic Acid and Glutamic Acid. The presence of additional phosphoresidues also facilitates CK1 phosphorylation. These acidic motifs presumably help recruit and orient the kinase appropriately to enable efficient phosphorylation of the target residues."
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "response": "Unfortunately, the given passage does not contain information about the different proteins or isoforms encoded by the ASPH gene in humans. The passage discusses the aspA gene of Escherichia coli bacteria, including details about cloning it into a plasmid vector, determining its nucleotide sequence, and analyzing the sequence to predict properties of the protein it encodes.\n\nSince the passage does not mention the human ASPH gene or the proteins it encodes, I do not have enough information to directly answer the question that was asked about the different ASPH proteins/isoforms in humans. Based on the background provided, it seems the question may have been intended for a different passage that specifically discussed the human ASPH gene and proteins. Without additional context about ASPH in humans, I cannot provide the requested details about the proteins encoded by that gene. Please let me know if you would like me to try to answer a different question or provide additional clarification."
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "response": "Based on the document, there is no clear information on exactly when empagliflozin was FDA approved. The document discusses a study investigating potential pharmacokinetic drug-drug interactions between empagliflozin and other medications in patients with type 2 diabetes mellitus. It states that empagliflozin is \"a potent, selective sodium glucose cotransporter 2 inhibitor approved for the treatment of type 2 diabetes mellitus\", but does not give a specific FDA approval date. Since the document focuses on a study evaluating drug interactions, rather than approval information, it unfortunately does not provide the specifics on when FDA approval occurred for empagliflozin. Apologies that a clear approval date is not available in this text."
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "response": "Unfortunately, the provided information does not specifically state the results of loss of the Lon1 protein in Arabidopsis. The information discusses the roles of Deg2 protease and redundant D1 degradation pathways under light stress conditions. However, here is what I can infer based on the background provided:\n\nThe passage discusses how the D1 protein in photosystem II gets damaged under high light conditions in plants, and needs to be degraded and replaced constantly. It suggests that multiple degradation pathways and proteases like Deg2 are involved. Lon1 has also been studied as one of the proteases hypothesized to be involved in degrading damaged D1 protein. \n\nSo while the information does not directly state the effects of loss of Lon1, one could reasonably suggest or predict that loss of Lon1 protease activity in Arabidopsis may negatively impact D1 protein turnover, and consequently, decrease plant's ability to deal with photodamage under high irradiances. This may result in reduced growth or photosynthetic efficiency in Lon1 mutants compared to wild-type when exposed to high light. However, effects may not be too dramatic because of the redundant degradation pathways and other proteases like Deg2. \n\nFurther research targeting Lon1 specifically in Arabidopsis would be needed to confirm its actual physiological roles and phenotypic effects from its loss under high light conditions. But this is the extent of reasonable inference I can make from the background provided in your question. Please let me know if you need any clarification or have additional information to add."
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "response": "Based on the information provided, there is no clear evidence stating whether a linker histone exists in the yeast genome. The document discusses linker histones in the context of Caenorhabditis elegans (a worm) and their ability to enhance telomeric position effect in budding yeast when tested in an assay. Specifically:\n\n- The document states that linker histones are nonessential for the life of single-celled eukaryotes, but does not directly specify if yeast (which are single-celled eukaryotes) have linker histones or not. \n\n- Linker histones from C. elegans were tested for their ability to affect telomeric position effect in budding yeast in the assay described. Only one out of seven linker histones from C. elegans enhanced the effect. This suggests budding yeast has some similar telomeric chromatin silencing mechanisms as C. elegans that can interact with the worm linker histones. However, it does not confirm or deny the existence of native linker histones in yeast itself.\n\nSo in summary, while the document analyzes the effect worm linker histones can have in a yeast assay, it does not clearly state or provide enough evidence to determine if a linker histone naturally exists within the yeast genome itself. The information focuses on C. elegans rather than conclusively answering the status of linker histones and their existence in yeast specifically."
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "response": "Yes, there is evidence from the document provided that tomato juice lowers cholesterol levels. Specifically:\n\n- The study aimed to show the supplementation effect of tomato juice on metabolic health indices, including serum lipid levels, in generally healthy people. \n\n- Tomato juice supplementation significantly reduced serum levels of cholesterol. This reduction was seen even when subjects were stratified by body fat change.\n\n- The reduction in serum cholesterol levels remained statistically significant after adjusting for potential covariables like changes in body fat.\n\nSo this randomized controlled trial found that daily tomato juice supplementation led to reduced serum total cholesterol levels in young healthy women, suggesting that tomato juice has a cholesterol-lowering effect. The document provides clear evidence supporting the cholesterol-lowering impact of tomato juice."
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "response": "Based on the information provided, a few key points regarding how Hsp70 and Hsp110 affect mRNA stability:\n\n1) The HSP70 mRNA itself becomes less stable and its levels decrease under stress conditions like heat shock and arsenite treatment. This suggests regulation of HSP70 expression occurs mainly at the transcriptional level.\n\n2) Accumulation of HSP70 mRNA under stress conditions in the presence of cycloheximide (which blocks new protein synthesis) suggests that some newly synthesized protein(s), possibly HSP70 itself, are involved in negatively regulating hsp70 gene expression at the transcriptional level. \n\n3) Stress conditions that inhibit normal protein synthesis also delay the transcriptional inactivation/decay of HSP70 mRNA levels.\n\n4) No information is provided regarding the specific role of Hsp110 in regulating mRNA stability. The passage focuses on regulation of HSP70 expression and mRNA stability.\n\nIn summary, newly synthesized stress proteins like HSP70 appear to negatively regulate their own hsp70 gene expression at the transcriptional level, contributing to instability/decay of HSP70 mRNA under stress. Hsp110 is not directly addressed with regards to its impact on mRNA stability based on the provided information."
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "response": "Based on the information provided in the passage, there is no direct mention of which deiodinases are present in skeletal muscle. The passage discusses the presence of type I (DI) and type II (DII) iodothyronine deiodinases in human coronary artery smooth muscle cells (hCASMCs) and human aortic smooth muscle cells (hASMCs). Specifically:\n\n- DI is widely distributed and maintains circulating T3 levels\n- DII is present in a limited number of tissues to provide intracellular T3\n- The passage demonstrates the expression of DII, regulated by a cAMP-mediated mechanism, in human vascular smooth muscle cells\n\nHowever, there is no information presented regarding which deiodinases are present in skeletal muscle. The passage is focused on vascular smooth muscle cells and does not discuss skeletal muscle. So unfortunately, the passage does not provide enough information to directly answer the question about which deiodinases are present in skeletal muscle."
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "response": "Based on the information in the document, the inflammatory caspase proteins that can be listed are:\n\n- Caspase-1\n- Caspase-4\n\nSpecifically, the document mentions that caspase-1 is activated in innate immune complexes called inflammasomes and is important for regulating inflammation. Caspase-4 is also shown to play a role in inflammation by interacting with and activating caspase-1. The document demonstrates that caspase-4 expression is required for activation of proIL-1 and inflammasome-dependent processes related to inflammation. Therefore, caspase-1 and caspase-4 can be listed as inflammatory caspase proteins based on the information provided."
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "response": "Unfortunately, there is no mention of a link between the aurora B kinase and the polycomb protein ring1B in the provided document. The document discusses research examining the regulation of aurora B kinase levels and activity over the cell cycle. Specifically, it finds that:\n\n1) Aurora B kinase protein levels fluctuate over the cell cycle, peaking in mitosis and dropping in G1. \n\n2) Aurora B is a substrate of the anaphase-promoting complex/cyclosome (APC/C) - a ubiquitin ligase that is activated by the Cdh1 protein. APC/C-Cdh1 ubiquitinates Aurora B, targeting it for degradation at the end of mitosis. \n\n3) Cdh1 is required for the degradation of Aurora B at the end of mitosis. When Cdh1 levels are reduced, Aurora B is stabilized.\n\nHowever, the polycomb protein ring1B is not mentioned. Based on the information provided, there does not appear to be any evidence presented linking aurora B kinase and ring1B. The document is focused solely on examining the cell cycle-dependent regulation of aurora B levels and activity by APC/C-Cdh1. Hopefully this summary is helpful in clarifying that no link between aurora B and ring1B is discussed in the given information. Please let me know if you need any clarification or have additional questions!"
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "response": "Based on the information in the document, there does not appear to be a direct statement about the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates. However, some relevant information is provided:\n\n1) At donor sites, the higher the homology to the 9-nucleotide consensus sequence, the more likely the site is to be an actual donor site. This suggests the consensus motif is the most important. Non-canonical motifs are not specifically discussed.\n\n2) At acceptor sites, homology to the 15-nucleotide consensus motif alone is a poor criterion to distinguish real acceptor sites. Instead, the weighted homology scores of the 40-60 nucleotide intron-exon sequence surrounding the acceptor site works better. This suggests non-canonical motifs in this larger sequence likely play an important role.\n\n3) Nucleotide frequencies around splice junctions seem to differ between human, rat, mouse and chicken, suggesting species-specific motifs may be relevant. \n\nHowever, the passage does not provide clear information about which specific non-canonical motifs are most frequent or important at donor and acceptor sites across vertebrates. More detailed analysis of splice site sequences in various vertebrate genomes would be needed to determine that. The document focuses more on overall principles rather than specific non-canonical motifs."
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "response": "Based on the information in the document, the event that results in the acetylation of S6K1 is growth factor stimulation. Specifically:\n\n- The document states that in addition to phosphorylation, S6K1 is also targeted by lysine acetylation. Using tandem mass spectrometry, they mapped the acetylation site to lysine 516.\n\n- Using acetyl-specific K516 antibodies, they show that acetylation of endogenous S6K1 at this site is \"potently induced upon growth factor stimulation.\"\n\n- Although S6K1 acetylation and phosphorylation are both induced by growth factor stimulation, the document indicates these events appear to be functionally independent. \n\n- Experiments using inhibitors and stresses indicate that S6K1 acetylation can occur in the absence of phosphorylation and vice versa.\n\nSo in summary, the key event that induces and results in the acetylation of S6K1 at lysine 516 based on this information is growth factor stimulation."
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "response": "Unfortunately, the information provided does not mention episodic ataxia type 6 specifically. It talks about episodic ataxia type 2, which is a separate condition caused by mutations in the CACNA1A gene on chromosome 19p13.\n\nSpecifically, it describes research on a large Italian family with episodic ataxia type 2. The researchers were able to further narrow down the region on chromosome 19p13 that contains the CACNA1A gene responsible for episodic ataxia type 2.\n\nHowever, there is no information provided about the cause or genetics of episodic ataxia type 6. Based on the limited information given, I do not have enough details to provide a direct answer as to what causes episodic ataxia type 6. Perhaps in a follow-up question you could provide more background on that specific type or clarify if you intended to ask about the cause of type 2 instead. Let me know if you need any clarification or have additional questions!"
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "response": "Based on the information provided, there is no clear evidence regarding the presence or absence of chromomethylases in animal genomes. The passage discusses a transcriptome analysis comparing fat-tailed and short-tailed sheep breeds, focusing on genes related to fat metabolism and deposition. It does not specifically mention chromomethylases.\n\nChromomethylases are enzymes that catalyze the transfer of methyl groups to chromatin, playing a role in epigenetic gene regulation. Their presence and functionality have been studied more extensively in plants than animals. Further targeted research would be needed to determine if functional chromomethylases exist and play a regulatory role in animal genomes. The transcriptome study described here does not seem to directly address this question. Additional genomic or epigenetic analyses searching specifically for chromomethylase genes or activity would be informative. But the information provided in this passage does not definitively answer whether chromomethylases are present in animal genomes."
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "response": "Here are some of the main R/Bioconductor packages for transcription factor binding site (TFBS) analysis:\n\n- TFBSTools - Contains functions for studying transcription factor binding sites, including tools for enrichment analysis, comparing TFBS motifs, scanning sequences for motifs, and more.\n\n- PWMscan - Scans DNA sequences for transcription factor binding sites using position weight matrices (PWMs). Includes PWM databases and functions to scan FASTA files or DNA sequences.\n\n- DECIPHER - Tools for analyzing, visualizing, and manipulating DNA sequence motifs, including functionality for searching sequences for known motifs, comparing motifs, generating logos, etc.\n\n- Biostrings - Includes functionality for representing, storing, searching, and manipulating biological sequences. Useful for working with DNA sequences and scanning for motifs. \n\n- MotIV - Integrates databases of position weight matrices (PWMs) for prediction of TFBSs. Provides tools to search sequences for matches to PWMs in various databases.\n\n- PWMEnrich - Identifies enriched TFBS motifs in a set of DNA sequences using known PWMs. Implements several major motif enrichment algorithms.\n\n- TFBStools - Provides tools for predicting TFBSs by scanning sequences usingPWM models and for visualizing predicted binding sites. Interfaces with the JASPAR database.\n\nSo in summary, key packages provide motif databases, tools to scan sequences for known motifs, compare and analyze novel motifs, visualize motifs, and identify enriched motifs in a set of sequences. Many packages integrate with existing PWM and TFBS databases."
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "response": "Based on the background provided, there is no mention of specific clinical trials focused on prevention of sarcopenia. The background discusses a retrospective analysis looking at the association between sarcopenia (defined by skeletal muscle index measurements at L3 and pectoralis muscle) and outcomes in DLBCL patients treated with R-CHOP therapy. It does not discuss any interventional trials or preventative strategies for sarcopenia. \n\nTherefore, there is no list of clinical trials for prevention of sarcopenia provided in the text to summarize. The analysis simply suggests that sarcopenia is associated with worse treatment toxicity, treatment discontinuation, and overall survival in DLBCL patients. However, it does not mention or investigate any preventative measures for sarcopenia."
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "response": "Unfortunately, the given text does not specifically mention a database of molecular recognition features in membrane proteins. It describes research that developed a membrane proteomics method to identify integral membrane proteins. This involved steps such as in-solution acid hydrolysis, chromatographic separation, enzymatic digestion, and mass spectrometry analysis. When applied to membrane proteins from Synechocystis sp., this method identified 155 out of a predicted 706 integral membrane proteins. While this research describes progress in analyzing the membrane proteome, it does not name or describe a specific database of molecular recognition features in membrane proteins. Based on the information provided, there does not seem to be enough detail to directly answer the question asked about a database. I do not have additional knowledge about such a database. Please let me know if you need any clarification or have additional information to provide."
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "response": "Based on the information in the passage, rivaroxaban is not primarily metabolized or eliminated by the kidneys. The passage states:\n\n\"Dabigatran is mainly eliminated via the kidney, hence requiring dose-adjustment in case of moderate renal insufficiency, and contra-indicated in case of severe renal insufficiency. Rivaroxaban being excreted via kidney and liver, some precautions should apply in case of liver insufficiency.\"\n\nSo dabigatran is mainly eliminated by the kidneys, while rivaroxaban is excreted by both the kidneys and the liver. This suggests that rivaroxaban is not primarily metabolized or dependent on the kidneys alone for elimination. Rather, it relies on both kidney and liver metabolism and excretion. So the answer is no, rivaroxaban is not solely metabolized in the kidneys."
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "response": "Unfortunately the document does not clearly state which genes are regulated by TRalpha2 in the heart. The document discusses interactions between PPARalpha and thyroid hormone receptors (TRs) in regulating gene expression in the heart, but does not specify any genes that are directly regulated by TRalpha2 specifically. \n\nThe document shows that a mutation in TRbeta1 (Delta337T) affects the regulation of some PPARalpha target genes like UCP3 and MTE1, indicating cross-talk between the two pathways. And it notes that protein levels of TRalpha1 and TRalpha2 were changed in the mutant mice. But there is no clear statement about direct TRalpha2 gene targets. \n\nThe closest information is that UCP3 gene expression normally increases in response to PPARalpha ligand, but this induction was blocked in mice with defective TRbeta1. This suggests TRbeta1 somehow interacts with or facilitates PPARalpha regulation of UCP3. But it does not indicate that TRalpha2 directly regulates UCP3 or other specific genes.\n\nIn summary, while the document discusses interactions between TRs and PPARalpha in the heart, it does not clearly identify particular genes that are directly regulated by TRalpha2 specifically in cardiac tissue. It focuses more on TRbeta1 effects on PPARalpha target genes. Hopefully this helps explain why a clear answer cannot be extracted about the specific question asked. Let me know if you need any clarification or have additional questions!"
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "response": "Here are some biomedical question answering systems that are available:\n\n- AskHERMES: A web-based question answering system focused on clinical questions using biomedical knowledge graphs.\n\n- Dr. QA: An open-domain question answering system by the Allen Institute for AI that can answer questions related to biology, medicine, and health. \n\n- BioBERT: A language representation model trained on biomedical and clinical text that can be fine-tuned for question answering. \n\n- ClinicalBert: A version of BERT pre-trained on clinical notes and then fine-tuned for clinical question answering.\n\n- emrQA: A dataset and models for question answering over electronic medical records.\n\n- MedQuAD: A question answering dataset and benchmarks focused on the medical domain.\n\n- BioASQ: A challenge focused on biomedical semantic indexing and question answering, providing training datasets. \n\n- PubMedQA: A dataset for question answering over PubMed abstracts.\n\nSo in summary, some of the major biomedical QA systems and benchmarks include AskHERMES, Dr. QA, BioBERT, ClinicalBert, emrQA, MedQuAD, BioASQ, and PubMedQA. Many leverage recent advances in language models and neural networks for QA."
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "response": "Unfortunately, the provided information does not appear to contain any information to answer the specific question \"Which transcription factor activates the betalain pathway?\". There is no mention of the betalain pathway or any transcription factors in the given text, rather it discusses eukaryotic initiation factor 2 (eIF-2), ternary complexes, and reticulocyte lysates. Without any relevance to the question asked, I do not have enough context to provide a reasonable response. I apologize that I could not be more helpful - perhaps with some additional relevant background or clarification on how this information connects to betalain pathways and transcription factors, I could attempt another answer. Please let me know if you can provide any further information or context related to your original question."
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "response": "Based on the information in the passage, some preferred technologies for the enrichment for phosphorylated peptides include:\n\n- ERLIC (electrostatic repulsion-hydrophilic interaction chromatography) - The passage states that their ERLIC-based strategy enriched considerably longer and more acidic phosphopeptides compared to affinity-based methods using Ti(4+).\n\n- SCX (strong cation exchange) or RP (reversed phase) - The passage mentions using a simple solid-phase extraction step by SCX or RP prior to LC-MS analysis in their phosphoproteomics strategy.\n\n- Affinity-based enrichment methods using Ti4+ - While the passage states their ERLIC method performed better, affinity-based methods using Ti4+ are still a technology used for enriching phosphorylated peptides.\n\nSo in summary, ERLIC, SCX, RP, and Ti4+ affinity are some preferred technologies mentioned in the passage for enriching phosphorylated peptides in global quantitative phosphoproteomic analyses."
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "response": "Based on the information provided, there is no mention of the Palmini classification. The passage discusses two other classification systems:\n\n1) DSM-III - The Diagnostic and Statistical Manual of Mental Disorders, 3rd edition. This is published by the American Psychiatric Association and is used to diagnose mental disorders.\n\n2) CATEGO4-derived ICD-8 - The 4th edition of the CATEGO system, which derives diagnoses from the International Classification of Diseases, 8th revision (ICD-8). The ICD is published by the World Health Organization. \n\nThe passage compares diagnosis agreement between these two classification systems over different time frames (present state vs lifetime illness). It finds shifts in diagnosis by the DSM-III over time, with more cases being classified as affective disorders for lifetime illness compared to anxiety disorders for present state. \n\nHowever, there is no mention of the Palmini classification or which disorder it may classify. The passage is focused on the DSM-III and ICD-8/CATEGO4 systems. Without more context or information provided on the Palmini system, I do not have enough details to definitively state which disorder it rates."
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "response": "Based on the information provided, it seems that while the exact viral cause of subacute thyroiditis is unknown, there is some evidence to suggest a possible viral etiology:\n\n1) The document mentions that subacute thyroiditis is \"presumed to be caused by a viral infection.\" So there seems to be a general belief or hypothesis that viruses play a role, even if the specific virus(es) have not been definitively identified. \n\n2) The document describes two sisters, where the older sister had a typical case of severe subacute thyroiditis requiring hospitalization. Three weeks later, the younger sister developed the same clinical illness \"after nursing her.\" This temporal sequence and exposure suggests the illness could have been transmitted from the older to younger sister, possibly implying a viral infectious origin.\n\n3) The document concludes by postulating that subacute thyroiditis might be transmissible in \"genetically predisposed individuals.\" This suggests there could be viral transmission, especially in people with a genetic susceptibility. \n\nIn summary, while many details are still unknown, the information provided indicates scientists believe viruses likely play a role in the etiology or cause of some cases of human subacute thyroiditis. The familial illness description also raises the possibility of viral transmission and genetic factors interacting to enable development of the disease. More research seems needed to make definitive conclusions, but initial evidence points toward viral involvement."
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "response": "Based on the information provided, it does not appear that STAT3 is directly involved in EIF2AK2-dependent suppression of autophagy. The key points from the document are:\n\n- STAT3 expression is correlated with tumor growth, metastasis, and prognosis, and has been implicated in regulating autophagy. \n\n- Inhibiting autophagy increased chemosensitivity of castration-resistant prostate cancer (CRPC) cells.\n\n- Docetaxel treatment induced autophagy which was inhibited by STAT3 activation. This resulted in more mitochondrial damage and decreased CRPC cell viability. \n\nThe document suggests that activated STAT3 can inhibit chemotherapy-induced autophagy in prostate cancer cells, thereby promoting cell survival and chemoresistance. However, there is no mention of EIF2AK2 or its role in suppressing autophagy. The mechanism described seems to involve STAT3 modulating autophagy in response to chemotherapy treatment, rather than EIF2AK2 regulating autophagy.\n\nSo based on the information provided in the document, there does not seem to be evidence for STAT3 being involved in EIF2AK2-dependent autophagy suppression. The document focuses on STAT3's role in modulating chemotherapy-induced autophagy in prostate cancer cells. Involvement of EIF2AK2 is not described."
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "response": "Based on the document, Theatre is not mentioned. The document describes BamTools, which is a software suite that provides a C++ API and command-line toolkit for working with BAM files. Specifically:\n\n- BamTools facilitates research analysis and data management using BAM files, which are compressed binary formats for storing genomic sequencing alignment data. It provides efficient access to the alignment results in BAM files.\n\n- It includes various data management capabilities like filtering, merging, sorting BAM dataset. This simplifies many genomic data analysis tasks.\n\n- BamTools runs on Linux, Mac OSX and Windows. The source code and documentation is freely available.\n\nSo in summary, BamTools helps programmers and researchers work with large genomic sequencing datasets stored in BAM files by providing both an API and command line tools. The document does not mention anything about a Theatre software tool for genomic analysis."
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "response": "Based on the information provided, the Smith-Waterman algorithm has a time complexity that depends on the lengths of the two sequences being aligned. Specifically:\n\n- The Smith-Waterman algorithm uses dynamic programming to align two sequences. \n\n- It has a time complexity of O(mn) where m and n are the lengths of the two sequences. This means the execution time grows proportionally to the product of the lengths of the input sequences.\n\nSo in summary, the Smith-Waterman algorithm has a quadratic time complexity of O(mn) relative to the input sequence lengths m and n. This means it can be slow for very long sequences, but is guaranteed to find the optimal local alignment. The information talks about optimizations to improve the practical runtime by reducing memory accesses, but the asymptotic time complexity remains quadratic."
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "response": "Unfortunately, the passage does not clearly state which SLC family FLVCR1 is a member of. The passage discusses various atypical SLC families and their properties, including the MFSD, SV2, SPNS, and UNC93 families, as well as CLN3 which does not yet belong to any Pfam clan. However, it does not mention which family FLVCR1 belongs to. Based on the information provided, I do not have enough context to determine which SLC family FLVCR1 is a part of. The passage does not contain any information about FLVCR1 specifically. So I do not have sufficient knowledge to reasonably answer which SLC family FLVCR1 is a member of. I apologize that I could not provide a more specific response. If further details on FLVCR1's family membership were provided, I would be happy to re-analyze and provide an updated response."
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "response": "Based on the information in the passage, the list of GATA-1 interacting partners discovered with the help of the biotinylation tagging approach is not provided. The passage discusses using a strategy involving the creation of altered specificity mutants through a combination of two yeast two-hybrid screens to assess the functional relevance of protein-protein associations, but does not provide details on specific interacting partners of GATA-1 discovered through this biotinylation tagging approach. The passage mentions that GATA-1 interacts with a multitude of other nuclear proteins, including FOG-1, EKLF, CBP/p300, and Lmo2, but these were discovered through yeast two-hybrid screens, not the biotinylation tagging approach that is the focus of the question. Since the specific information requested in the question is not present in the given passage, there is no list to provide based on the information given."
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "response": "Unfortunately, the question does not provide clear information about the specific interaction between TAF10 and the GATA1 transcription factor or the outcome of such an interaction. \n\nThe provided document discusses interactions between the Dorsal and Twist transcription factors with TAF(II) subunits, specifically TAF(II)110 and TAF(II)60, in Drosophila and how these interactions regulate mesoderm gene expression in fly embryonic development. However, it does not mention TAF10 or GATA1, which are not Drosophila proteins.\n\nTAF10 is a subunit of the general transcription factor TFIID complex in mammals and other organisms. GATA1 is a transcription factor important for gene regulation during erythropoiesis and megakaryopoiesis in vertebrates. Without more context about the functional relationship between TAF10 and GATA1, I unfortunately cannot provide insight into the phenotypic or molecular outcome of these two factors interacting. Additional experimental background would be needed to address this specific protein-protein interaction and its biological impact. Please let me know if you have any other questions!"
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "response": "Based on the background and findings from the research study described, it does not appear that specific decision support systems for chronic pain management are mentioned. The study focuses on pain recognition, assessment and management in hospital settings, particularly for patients with dementia.\n\nSome key points:\n\n- The existing processes for guiding pain assessment and management are inadequate, especially for dementia patients.\n\n- The study proposes a revised theoretical model of decision making around pain for dementia patients in acute hospital wards. This model takes into account individual cognition, social interactions between staff, and organizational context.\n\n- The goal is to use this revised model to develop decision support interventions to improve pain assessment and management for dementia patients in hospitals.\n\nSo while decision support systems are proposed as an outcome of the study, the document does not report on any existing systems specifically for chronic pain management. The focus is on acute pain in hospitalized dementia patients. Hopefully this helps summarize the key points relevant to your question! Let me know if you need any clarification."
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "response": "Based on the information provided, it seems angiogenin is a protein that induces the formation of new blood vessels. The passage mentions that it is a member of the ribonuclease superfamily and that its surface loop region defined by residues 59-71 plays an important role in its angiogenic function.\n\nHowever, the passage does not provide clear information about the subcellular localization of angiogenin. Proteins can localize to various cellular compartments like the nucleus, cytoplasm, cell membrane, etc. But the text here does not specify where in the cell angiogenin is found. \n\nSo in summary, while the text discusses the function and important regions of angiogenin, it does not clearly state which subcellular compartment angiogenin localizes to. Without more context or background information, I do not have enough details to definitively state its subcellular localization. The available information focuses more on discussing the surface loop region and its role in angiogenin's overall angiogenic functionality."
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "response": "Based on the background information provided, ranolazine affects kinase signaling activation in the heart in the following way:\n\n1) Serum- and glucocorticoid-regulated kinase-1 (SGK1) is activated in heart failure in humans and mouse models. Overactivation of SGK1 contributes to cardiac dysfunction, arrhythmias, and sodium channel alterations.\n\n2) Ranolazine, which blocks the late sodium current, was able to reverse the proarrhythmic effects and sodium channel changes caused by overactivation of SGK1. \n\n3) Therefore, ranolazine indirectly affects kinase (specifically SGK1) signaling activation by mitigating some of the downstream effects of elevated SGK1 activation, including arrhythmias and sodium channel dysfunction. However, the document does not indicate that ranolazine directly inhibits or downregulates SGK1 kinase activity itself.\n\nIn summary, ranolazine lessens some of the pathological effects associated with abnormally high SGK1 signaling in heart failure, but does not appear to directly target or suppress SGK1 kinase activation per se based on the background provided. It works downstream by blocking late sodium current to restore function."
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "response": "Based on the information in the provided document, it does appear that the regulation of Vsr endonuclease is dependent on the growth phase of bacteria. Specifically, the document states that \"Vsr endonuclease levels are growth phase dependent\" and that \"Decreased production of Vsr relative to Dcm during the log phase may contribute substantially to the mutability of 5-methylcytosine.\" This suggests that Vsr endonuclease levels vary across different growth phases, unlike the Dcm cytosine methylase which is maintained at a constant level. So in summary, yes, the regulation of Vsr endonuclease seems to be correlated with and dependent on the bacterial growth phase."
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "response": "Based on the document, some of the key computational tools and methods for predicting beta-barrel transmembrane proteins are:\n\n1. EVfold - A maximum-entropy evolutionary coupling method for predicting residue contacts. This is combined with a machine learning approach (boctopus2) to predict beta-strands.\n\n2. boctopus2 - A machine learning approach for predicting beta-strands in the barrel region of transmembrane beta-barrel proteins. This is combined with EVfold.\n\n3. Template-based modeling (TM score) - Used to assess the accuracy of the 3D structural models generated. The document reports average TM scores of 0.54 for the transmembrane barrel regions of models generated by EVfold_bb.\n\n4. Sequence information - The prediction accuracy is related to the amount of sequence information available. More diverse homologous sequences for a given beta-barrel protein enables more accurate contact and structure prediction.\n\nIn summary, the key computational approaches are coevolution analysis (EVfold) combined with machine learning (boctopus2) to predict contacts and strand regions, alongside template-based model evaluation. Increasing sequence availability also enables progress in this area."
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "response": "Based on the information provided, there is no clear mention of the Galassi classification or what disorder it is used for. The passage discusses using latent class analysis (LCA) to categorize people into classes and identify items that best distinguish between those classes, based on responses to the Peters et al. delusions inventory. \n\nThe study looked at 82 patients diagnosed with a psychotic disorder and 210 healthy controls. It identified 4 classes - a normative one, and 3 related to dimensions of psychosis (paranoia, grandiosity/hypomania, and schizophrenia-like).\n\nHowever, there is no reference to the Galassi classification or what specific disorder it may classify. The passage focuses on using statistical analysis to potentially distinguish categories within the broader spectrum of psychoses. But no clear link is made to the Galassi classification system. Without more context or background information provided in the question, I unfortunately do not have enough information to determine what disorder the Galassi classification is used for. Please provide some additional details if you have any that could help identify the relevance of the Galassi classification."
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "response": "Unfortunately I do not have enough information to provide a specific list of common features of Shapiro syndrome. Shapiro syndrome appears to be a very rare condition, and details on its key features are limited in my knowledge base. In general though, syndromes are typically characterized by a set of symptoms or features that tend to appear together and indicate an underlying genetic or developmental disorder. To compile a reasonable list of common features for Shapiro syndrome specifically, more authoritative medical sources on this condition would need to be consulted. The information provided in the question describes features of Rubinstein-Taybi syndrome, which is a separate and distinct syndrome from Shapiro syndrome. My apologies for not being able to generate a list based on the background provided. Please feel free to provide additional information that may help identify defining characteristics of Shapiro syndrome."
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "response": "Unfortunately, the document provided does not mention BRAG1 or provide any information linking a disease to mutations within BRAG1. The document discusses X-linked hydrocephalus, spastic paraplegia type I (SPG1), and MASA syndrome being caused by mutations in the L1CAM gene on the X chromosome. It does not mention BRAG1. Based on the information given, there is no disease linked to mutations within BRAG1 mentioned. The document focuses on diseases caused by mutations in the L1CAM gene rather than BRAG1."
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "response": "Based on the information provided, the main inhibitor of protein phosphatase 1 (PP1) mentioned in the passage is inhibitor-2. Specifically, the passage states:\n\n\"We also found that the iron level associated with native PP1 is decreased by incubation with inhibitor-2, consistent with a function of inhibitor-2 as a PP1 chaperone.\"\n\nThis directly indicates that inhibitor-2 acts as an inhibitor and chaperone for PP1. Therefore, the main inhibitor of PP1 discussed in the given information is inhibitor-2."
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "response": "Based on the document, several key points can be made about the mechanisms underlying adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis:\n\n1) Multiple mechanisms are involved in generating mutations during adaptive mutagenesis in non-growing B. subtilis cells under stress. \n\n2) Transcription and transcription-associated proteins seem to influence adaptive mutagenesis. Specifically, the Mfd protein, which facilitates removal of stalled RNA polymerase and recruitment of repair proteins, has a role. Loss of Mfd has a depressive effect on stationary-phase mutagenesis.\n\n3) There appears to be an association between components of the transcription machinery like Mfd and the generation of mutations during adaptive mutagenesis. The mechanisms likely involve Mfd helping cells deal with issues during transcription that could lead to mutation generation, such as stalled RNA polymerase.\n\nIn summary, transcription processes and proteins that deal with transcriptional stress seem to be involved in driving the mutations underlying adaptive mutagenesis in stationary-phase B. subtilis cells. Multiple interconnected mechanisms related to transcription appear to contribute to producing the mutations."
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "response": "Erucism is a skin reaction caused by contact with the irritating hairs or spines of some caterpillars. When the hairs or spines penetrate the skin, they release toxins that cause an inflammatory reaction, leading to symptoms like burning pain, redness, swelling, blisters, and sometimes numbness, headaches, fever, vomiting, and rash. \n\nThe most common caterpillars that cause erucism are:\n\n- Puss caterpillars\n- Saddleback caterpillars \n- Io moth caterpillars\n- Pine processionary caterpillars\n\nThe toxins come from the caterpillars themselves or from plants they have eaten. The severity of symptoms can vary based on the type of caterpillar, the extent of contact, and the individual's sensitivity. \n\nDiagnosis is usually made clinically based on the appearance of the rash and a history of exposure to caterpillars. Treatments focus on relieving symptoms, and may include ice packs, antihistamines, steroids, analgesics, and antibiotics if infection occurs. Preventing further contact is important, as is avoiding scratching or rupturing blisters. Most cases resolve within a week or two but can be very painful in the meantime."
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "response": "Based on the information provided, some key indications for hydrochlorothiazide include:\n\n- Hypertension (high blood pressure): Hydrochlorothiazide is commonly used as a first-line agent to treat hypertension, either alone or in combination with other antihypertensive medications. It works by promoting the excretion of sodium and water to lower blood volume and pressure.\n\n- Edema (fluid retention): Hydrochlorothiazide is used to treat edema or swelling caused by conditions like heart failure, liver failure, and kidney disease. By promoting sodium and water excretion, it helps reduce excess fluid accumulation. \n\n- Nephrolithiasis (kidney stones): Hydrochlorothiazide is sometimes used to prevent recurrent calcium kidney stone formation, as it lowers calcium excretion into the urine.\n\nThe information discusses some quality control and formulation compatibility testing that was done on generic and compounded versions of hydrochlorothiazide. It found evidence that some formulations were not pharmaceutical equivalents or had unsatisfactory test results, often related to incompatibility with common excipients like lactose and mannitol. However, this does not change the main indications for the use of hydrochlorothiazide as outlined above. Let me know if you need any clarification or have additional questions!"
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "response": "Unfortunately, the provided document does not clearly state whether silicon has been used in the treatment of incontinence. The document mentions the injection of \"PTQ\" bulking agents and an adverse immune response to silicone injection in humans, but does not specify if PTQ contains silicone or if silicone has been used to directly treat incontinence. \n\nThe document does note that since the 1990s, injectable bulking agents have been used to treat fecal incontinence due to internal anal sphincter defects. It also reports two cases of giant cell foreign body reaction after injection of PTQ. However, it does not confirm whether PTQ contains silicon or provide a definitive answer regarding the use of silicon in incontinence treatment.\n\nWithout more context or background information, I cannot reliably confirm or deny from the provided document whether silicon has been used to treat incontinence. I would need more details on the composition of PTQ, as well as evidence clarifying whether silicon-containing substances have been used as injectable bulking agents for treating incontinence, in order to make an accurate assessment. The provided information is simply too limited and inconclusive. Please let me know if you have any other questions!"
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "response": "Based on the information provided, there is no clear evidence presented linking the moon cycle and risk of rupture of intracranial aneurysms. The document discusses two case reports of middle-aged women with incidental aneurysms found on MRI who later had rupture. It raises the possibility that increasing perianeurysmal edema over time seen on imaging may correlate with higher risk of imminent rupture. However, the moon cycle is not mentioned. More research would be needed to determine if there is any correlation between the moon cycle and risk of intracranial aneurysm rupture. The document focuses on inflammatory changes in the aneurysm wall that could lead to rupture rather than astronomical or environmental factors like the moon cycle. Unless additional evidence is provided, the information given does not suggest an association between the moon cycle and rupture risk."
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "response": "Based on the information provided, there is no clear evidence to suggest that HuR protein regulates the splicing process. The document describes various functions and regulatory mechanisms of HuR, including:\n\n1) Regulates mRNA stability and translation of cell stress response proteins to affect cell fate\n\n2) Translocates into the cytoplasm upon lethal stress via association with pp32/PHAP-I\n\n3) Undergoes caspase-mediated cleavage at amino acid residue D226 in the cytoplasm. Non-cleavable mutant HuR isoform delays apoptosis.\n\n4) Association with pp32/PHAP-I and caspase-mediated cleavage contributes to amplified apoptotic response. \n\nHowever, the document does not mention anything about HuR regulating RNA splicing. The functions described focus on HuR's roles in mRNA stability, translation, and apoptotic signaling pathways. Without any evidence presented on splicing regulation, I do not have enough information to conclude that HuR regulates the splicing process. Let me know if you have any other documents or evidence specifically supporting a role for HuR in splicing that could further inform my response."
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "response": "Based on the document, some key functions and details about the prothymosin alpha c-terminal peptide are:\n\n1) Prothymosin alpha is an essential protein involved in immune stimulation and apoptosis regulation. This suggests the c-terminal peptide likely plays a role in these processes as well, since it is part of the prothymosin alpha protein.\n\n2) The c-terminal peptide contains the site of N-terminal acetylation that was discovered on prothymosin alpha produced in E. coli. Specifically, the N-terminal serine residue was found to be acetylated. This indicates the c-terminal peptide contains this modifiable N-terminal serine that may impact the protein's functions. \n\n3) The discovery of N-terminal acetylation on prothymosin alpha produced in E. coli adds a new clue about how this modification can occur in prokaryotes. This suggests the c-terminal peptide and its N-terminal serine are involved in understanding the mechanism of acetylation in prokaryotes.\n\n4) The c-terminal peptide was part of modified prothymosin alpha found to stimulate greater immune response. This points to the c-terminal peptide playing an augmenting role in the immune stimulation functionality of prothymosin alpha.\n\nIn summary, the key known functions of the prothymosin alpha c-terminal peptide based on the information provided are involvement in immune stimulation, apoptosis regulation, undergoing N-terminal acetylation, and providing clues into acetylation mechanisms in prokaryotes. Let me know if you need any clarification or have additional questions!"
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "response": "Unfortunately, the information provided does not clearly answer the question \"Which peptide plays a pivotal role in human cystatin C fibrillization?\". The given text discusses studies of the proline mutants of human stefin B, a protein related to cystatins, and their folding, oligomerization, and amyloid fibril formation. It compares findings to beta-2-microglobulin, a different protein involved in amyloidosis. However, it does not specifically state the peptide pivotal in human cystatin C fibrillization. It mentions domain and loop swapping activities in stefin B enabled by proline residues, but no clear information on cystatin C fibrillization. To directly answer the question about the peptide pivotal for human cystatin C fibrillization, additional information focused on that specific protein and process would be needed that does not seem to be provided in the text. Without that, I do not have enough context to definitively identify which peptide plays this key role."
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "response": "Unfortunately, the provided document does not clearly state whether the concentration of HIF-1α protein increases after administration of the cytoprotective prodrug amifostine (ethyol). The document discusses the radioprotective effects of amifostine and its ability to induce a significant increase in the acute-phase protein alpha-2-macroglobulin ((2)M). Specifically, it suggests that the upregulation of (2)M plays a central role in the radioprotection provided by amifostine. However, there is no mention of HIF-1α or changes in its concentration in response to amifostine treatment. So based on the information given, I cannot definitively state whether HIF-1α levels increase after amifostine administration. More targeted research evaluating the effects of amifostine on HIF-1α levels would be needed to answer this question."
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "response": "Based on the document, Set8/PR-SET7 is a histone methyltransferase that specifically monomethylates lysine 20 on histone H4 (H4K20me1). The document does not mention Set7 or any histone marks deposited by Set7. It focuses solely on how Set8/PR-SET7 monomethylates H4K20 through its interactions with the histone H4 peptide. So to answer the question \"Which histone marks are deposited by Set7?\", there is no evidence in the given document that Set7 deposits any histone marks. The document only discusses histone marks deposited by Set8/PR-SET7."
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "response": "Unfortunately the given document does not appear to explicitly state the number of disulfide bridges hepcidin has. The document discusses the folding mechanisms of two other proteins - 1WQE and 1PG1. It mentions that they contain disulfide bridges, but does not give specifics on the number for either protein. Since no information is provided on the number of disulfide bridges in hepcidin specifically, I do not have enough information to provide a definite answer to the question asked about how many disulfide bridges hepcidin has. The passage does not contain relevant information to answer that question based on the context given. I apologize that I don't have enough details in the provided information to respond with a direct answer. Let me know if you need any clarification or have additional information that could help determine an answer about the number of disulfide bridges for hepcidin."
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "response": "Based on the information provided, the protein encoded by the gene DNAJC11 is localized to the chloroplast stroma. The key evidence supporting this is:\n\n1) The document discusses Arabidopsis cDNAs encoding ATJ11, which is the smallest known J-domain protein. This suggests ATJ11 is the gene/protein in question.  \n\n2) It states that the precursor ATJ11 protein was synthesized in vitro and imported by isolated pea chloroplasts where it was localized to the stroma. This directly states the protein is localized to the chloroplast stroma.\n\nSo in summary, the document indicates that ATJ11, encoded by the Arabidopsis gene, is imported into chloroplasts and localized specifically to the chloroplast stroma. Therefore, the localization of the protein encoded by DNAJC11 is the chloroplast stroma."
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "response": "Based on the information provided, it seems that ultraconserved elements (UCEs) are generally depleted among copy number variants (CNVs) in the human genome, with some key exceptions:\n\n- UCE depletion characterizes most recent large-scale CNV datasets in humans, as well as de novo CNVs that have gone through meiosis at most once. This suggests UCE deletion/duplication is typically deleterious.\n\n- However, CNVs arising specifically in cancer cells are often not depleted and can even become enriched for UCEs. This may be because cancer CNVs are newly formed and have not yet established the typical UCE-depleted profile, or it could reflect the diseased state of cancer cells.\n\n- Supporting the diseased state explanation, somatic CNVs not associated with disease do show UCE depletion. \n\n- It is also possible for CNVs in induced pluripotent stem cells to become depleted for UCEs over time without meiosis, suggesting UCE-disrupting CNVs may be selected against.\n\nIn summary, typical/healthy CNVs tend to be depleted for UCEs, but exceptions exist like in cancer where this pattern is not seen, possibly relating to the disease state. Depletion may also become established over time in certain cell types without meiosis, via selection against disruptive CNVs."
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "response": "Based on the information in the document, the substrate of the haspin kinase during mitosis is not explicitly stated. The document discusses:\n\n- Haspin is a serine/threonine kinase that is highly expressed during cell proliferation and mitosis. It has emerged as a potential therapeutic target in oncology. \n\n- A high throughput screen identified an acridine analog as a potent inhibitor of haspin kinase. Profiling showed it also inhibited DYRK2, another serine/threonine kinase. \n\n- Structure-activity relationship studies allowed the generation of a potent and selective haspin kinase inhibitor, as well as a moderately potent and selective DYRK2 inhibitor.\n\nHowever, the specific substrate that haspin phosphorylates during mitosis is not clearly identified. The document discusses haspin's role and inhibition but does not reveal details about its mitotic substrate. Based on the information provided, I cannot definitively state what the substrate is. The answer would require more specific background knowledge on the molecular details of haspin's function."
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "response": "Based on the information provided, here is a summary of the key points regarding the mechanism of viroid replication, specifically for Citrus viroid III (CVd-III):\n\n- Viroids like CVd-III replicate via a rolling circle mechanism, which involves cleavage, replication of the monomeric strand, and ligation back into the circular structure.\n\n- For CVd-III, the cleavage and ligation steps require rearrangement of its highly base-paired native secondary structure. \n\n- Unlike Potato spindle tuber viroid (PSTVd), the loop E motif of CVd-III has a different tertiary structure, with two likely Watson-Crick GC base pairs that significantly stabilize it.\n\n- The initial cleavage event for CVd-III likely occurs on the 5' side of a GU wobble base pair, which is part of a helix involving a nearby pair of inverted repeats. \n\n- After the first cleavage, sequences at the 3' end rearrange into a hairpin containing identical base pairs (GC, GU, CG) as the initial cleavage site. \n\n- The second cleavage then occurs within this 3' hairpin. \n\n- The stable loop E motif of CVd-III is proposed to align the 5' and 3' termini after the second cleavage to allow the host ligase to join them back together.\n\nIn summary, CVd-III appears to use some different structural rearrangements compared to PSTVd during rolling circle replication, especially in terms of the stability of the loop E motif and location of the cleavage sites."
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "response": "Based on the information provided, it does seem that fibronectin constitutes a potential serum biomarker for Duchenne muscular dystrophy (DMD). A few key points:\n\n1) The study used a proteomics approach to identify candidate biomarkers in serum from DMD patients and controls. Fibronectin was chosen for further analysis based on significant differences observed between DMD and controls. \n\n2) ELISA testing showed a significant increase in fibronectin levels in DMD patients compared to age-matched controls. Levels in patients with other neuromuscular disorders were comparable to controls.\n\n3) Longitudinal analysis over 6 months to 4 years demonstrated progressive elevation of fibronectin levels in DMD patients.\n\n4) The authors conclude that serum fibronectin levels may be a promising biomarker to monitor disease progression in DMD.\n\nIn summary, based on the proteomic discovery, validation testing showing specificity to DMD, and longitudinal tracking of levels with disease progression, this study provides evidence to suggest fibronectin as a serum biomarker for Duchenne muscular dystrophy. More research would still be needed to further establish and standardize it as a clinical biomarker."
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "response": "Unfortunately, the question does not provide enough information for me to definitively state which major epigenome projects are contained in the DeepBlue epigenomic data server. The passage discusses the Epigenomics resource at the National Center for Biotechnology Information (NCBI), but does not mention the DeepBlue epigenomic data server specifically.\n\nThe passage states that the NCBI Epigenomics resource contains epigenetic data sets from the Gene Expression Omnibus (GEO) database, and provides some statistics on the current data holdings. However, without more context about the DeepBlue server, I cannot determine if there is any overlap or relationship between these two resources. \n\nTo answer this question accurately, more background information would be needed on what the DeepBlue epigenomic data server is, what epigenome projects it contains, and how it might relate to other public epigenomic data repositories like the one hosted by NCBI. Without those additional details, there is insufficient information provided in the passage or question to definitively state which major epigenome projects are present in the DeepBlue server. Please let me know if you can provide any clarifying details."
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "response": "Unfortunately, the question does not provide enough information for me to determine which specific tool employs self organizing maps for analyzing synonymous codon usage. The document talks about correspondence analysis of codon usage data and provides a web server for studying synonymous codon usage, but does not mention anything about self organizing maps. Without more context or background information, I cannot confidently name a tool that uses self organizing maps for the stated purpose. The document seems to focus more on correspondence analysis rather than self organizing maps. If any additional details are provided about the tool or methodology using self organizing maps, I would be happy to reconsider my response. But based on the information given, I cannot reasonably answer which tool employs those specific methods."
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "response": "Based on the information provided, MINDY-1 seems to refer to Mindboggle, which is an open source software platform for analyzing the shape and morphology of human brain MRI data. \n\nKey points about Mindboggle according to the document:\n\n- It is an open source brain morphometry platform that analyzes T1-weighted MRI data to output volumetric data, surface data, labels, features, and shape information about the brain that can be used for further analysis.\n\n- It can be used to study shape variation in healthy and diseased human brains.\n\n- It provides measures of volume, cortical thickness, curvature, surface area, depth, spectral shape features, etc. - more detailed shape analyses than most other software.\n\n- The goal is to provide sensitive biological markers for diagnosing and tracking mental health disorders.\n\n- It has been evaluated using a large manually labeled dataset of brain images and benchmarked against state-of-the-art algorithms.\n\nSo in summary, MINDY-1 seems to refer to the Mindboggle platform itself for analyzing and quantifying the shape of human brains from MRI data for research purposes. The document is describing the software's capabilities and applications."
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "response": "Based on the document, there is no clear mention of a software package specifically for the analysis of conserved genomic loci. The document discusses Genquire, which is a software package for visualization, querying, editing, and markup of genomic sequences and annotations. It allows display and analysis of various genomic databases and files. However, it does not seem to be focused on analyzing conserved loci specifically. The document does not provide enough information to definitively name a software package for conserved loci analysis. Additional documents or information may be needed to answer this question."
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "response": "Based on the information provided, here are 3 diseases associated with the PIEZO2 gene:\n\n1. Distal arthrogryposis - Dominant mutations in PIEZO2 can cause different forms of distal arthrogryposis. \n\n2. Loss of proprioception and touch sensation - The siblings with the homozygous PIEZO2 mutation displayed deficits in proprioception and touch sensation.\n\n3. Progressive contractures involving distal joints - The siblings with the homozygous PIEZO2 mutation had a progressive form of contractures involving the distal joints, distinct from the contractures caused by dominant PIEZO2 mutations."
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "response": "Based on the information provided, it seems that ERAP1-ERAP2 dimerization is not specifically discussed. The passage focuses on the role of ERAP1 in trimming peptides for MHC class I antigen presentation. Some key points are:\n\n- ERAP1 appears specialized to produce peptides presented on MHC class I molecules. It trimmed peptides 10 residues or longer but spared 8-residue peptides.\n\n- In vivo, ERAP1 enhanced production of an 8-residue ovalbumin epitope from longer precursors.\n\n- ERAP1 trimmed about half of 9-residue peptides tested, reducing the overall antigenic peptide supply in normal cells. \n\n- After interferon-gamma treatment caused proteasomes to produce more extended precursors, ERAP1 increased the peptide supply for MHC class I presentation.\n\nSo while the passage discusses functions of ERAP1, there is no mention of ERAP1-ERAP2 dimerization specifically, or what this might promote. The answer would depend on information that is not provided in the passage. Let me know if you have any other questions!"
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "response": "Unfortunately the provided document does not contain information specifically about the function of R-spondin 1 or noggin in non-damaged gallbladders. The document discusses the general role of R-spondins, including Rspo3, as secreted ligands that activate Wnt/-catenin signaling and play a role in developmental processes. It describes the production of a conditional Rspo3 allele in mice to study its function during development. The document mentions that combined mutations in Rspo3 and Rspo2 result in severe hindlimb truncations, indicating redundant roles, but there is no information provided on their function in gallbladders specifically. Without more context or background information on the biology of gallbladders, I do not have enough information to provide a reasonable answer or reply regarding the function of R-spondin 1 or noggin in non-damaged gallbladders. I apologize that the information given does not allow me to address the specific question asked. Please let me know if you have any other questions!"
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "response": "Based on the information in the document, NADPH oxidase 5 does require a subunit for function. Specifically, the document states that activity of phagocyte NADPH-oxidase relies on the assembly of five proteins, including the transmembrane flavocytochrome b(558) which consists of a heterodimer of the gp91(phox) and p22(phox) subunits. \n\nThe document goes on to state that they expressed the gp91(phox) and p22(phox) subunits and that the recombinant cytochrome b558 (consisting of these two subunits) displayed superoxide generation activity that was sensitive to inhibitors, similar to the activity seen in neutrophils. This indicates that the two subunits gp91(phox) and p22(phox) are required for the catalytic activity of NADPH oxidase.\n\nTherefore, based on this information, NADPH oxidase 5 does require the gp91(phox) and p22(phox) subunits to be assembled as cytochrome b558 in order to display oxidase catalytic activity and function. It relies on the assembly with these additional subunits."
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "response": "Based on the information in the document, there does not seem to be a direct connection made between furin and hepcidin. The document focuses on describing hepcidin - a 25-amino acid peptide hormone that is the main regulator of plasma iron concentrations - and its interaction with its receptor ferroportin.\n\nSpecifically, the key points regarding hepcidin from the document are:\n\n- Hepcidin binds to and induces internalization and degradation of its receptor ferroportin, which blocks iron efflux from cells into plasma. \n\n- Hepcidin is taken up by cells expressing ferroportin in a temperature and pH dependent manner, and is degraded together with ferroportin in lysosomes. \n\n- Hepcidin is not recycled after binding to ferroportin and inducing ferroportin's degradation. Only hepcidin degradation products are released from cells.\n\nThe document does not mention furin or establish any relationship between furin and hepcidin. Based on the information provided, there does not seem to be a connection described between the two. The document is solely focused on elucidating the fate of hepcidin after it binds to its receptor ferroportin."
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "response": "Unfortunately the document does not clearly state which is the largest metabolic gene cluster in yeast. It mentions the GAL gene cluster, but does not indicate if this is the largest one or provide information to compare it to the sizes of other metabolic gene clusters in yeast. The document focuses more on hypotheses for why metabolic gene clusters exist (coordinated gene expression and genetic linkage), rather than detailing the relative sizes of different clusters. So based on the information given, I cannot definitively state which is the largest metabolic gene cluster in yeast. The document does not provide enough specifics to directly answer that question. I would need more comparative information about multiple metabolic gene clusters in yeast to identify the largest one."
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "response": "Based on the document, the lncRNA MALAT1 plays several key roles in clear cell kidney carcinoma (KIRC):\n\n1) MALAT1 is upregulated in KIRC tumor tissues compared to normal tissues, based on TCGA data analysis. This suggests MALAT1 is involved in KIRC tumorigenesis.\n\n2) MALAT1 promotes KIRC cell proliferation and metastasis in vitro and in vivo. Mechanistically, this occurs via MALAT1 sponging (negatively regulating) miR-200s, which leads to increased expression of the miR-200s target ZEB2. \n\n3) Inhibition of MALAT1 expression may be a promising therapeutic strategy for treating KIRC, as reducing MALAT1 levels can partly reverse its stimulation of KIRC proliferation and metastasis. \n\nIn summary, the lncRNA MALAT1 acts as an oncogene in KIRC by sponging miR-200s and derepressing ZEB2 to drive tumor cell proliferation and metastasis. Targeting the MALAT1/miR-200s interaction represents a potential approach for KIRC therapy."
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "response": "Based on the information provided, there is no clear mention of a specific R/Bioconductor package for performing SNP enrichment analysis. The document talks about the SNPchip package, which contains classes and methods for storing, visualizing and analyzing high density SNP data, but does not indicate it is used specifically for enrichment analysis.\n\nSome possibilities of packages that may be relevant include:\n\n- GSEA - Gene Set Enrichment Analysis package, could potentially be applied to SNP data\n- genomeIntervals - Operations on genomic intervals with SNP data \n- SPAtest - Signaling Pathway Analysis methods, including enrichment analysis\n\nBut there is no definitive answer provided on a package just for SNP enrichment analysis. The document seems to focus more on the utility of the SNPchip package for SNP data storage, visualization and analysis in general. Additional context may be needed to determine if there is a standard R/Bioconductor package used specifically for SNP enrichment."
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "response": "Based on the information in the document, some key players on radial glial specification to ependymal cells appear to be:\n\n1. Stroke/ischemia: The document indicates that stroke acutely stimulated adult ependymal cell proliferation, causing them to divide and transform into radial glial cells. So stroke/ischemia seems to be a key trigger for this transition process.\n\n2. Dividing ependymal cells: The document states that the dividing ependymal cells took on radial glial cell genotype, phenotype and morphology. So the dividing ependymal cells themselves seem to be the key entity undergoing the transition into radial glial cells. \n\n3. Subventricular zone (SVZ): Increases in radial glial cells were shown to parallel the expansion of neural progenitors in the SVZ. Radial glial cells derived from the SVZ also supported neuron migration. This suggests the SVZ and its neural progenitor populations are involved in the ependymal to radial glial transition and functionality.\n\n4. Radial fibers of dividing cells: The document notes that a radial fiber was maintained throughout mitosis of the dividing ependymal/radial glial cells. This radial fiber may help enable their neural progenitor capabilities and scaffolding function to support neurogenesis and migration.\n\nSo in summary - stroke/ischemia, dividing ependymal cells, the SVZ niche, and the structural radial fibers of dividing cells seem to be key influences or players in radial glial fate and functionality following ependymal cell division. Let me know if you need any clarification or have additional questions!"
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "response": "Based on the information provided, triple negative gliomas are not specifically characterized. The passage discusses multicentric gliomas, which are a rare type of brain tumor where multiple tumors develop simultaneously in different parts of the brain.\n\nSome key points about the characterization of multicentric gliomas from the passage:\n\n- They were negative for mutant IDH1, indicating they do not have the common IDH1 mutation seen in many lower grade or secondary glioblastomas.\n\n- They were largely negative for 1p19q codeletion, which is a genetic signature commonly seen in certain types of brain tumors like oligodendrogliomas. \n\n- They had variable p53 mutation and EGFR amplification status.\n\n- They had loss of PTEN expression.\n\nSo in summary, multicentric gliomas display genetic and immunohistochemical features that distinguish them from more common IDH-mutant glioma subtypes. But there is no specific characterization of \"triple negative\" gliomas provided. The passage is focused on the unique aspects of multicentric gliomas only."
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "response": "Based on the background and information provided, TOPAZ1 refers to a novel protein that:\n\n- Stands for \"Testis and Ovary-specific PAZ domain gene\"\n\n- Has been identified through Suppression Subtractive Hybridization (SSH) as a new mammalian gene involved in oogenesis and early follicle development.\n\n- Encodes a protein containing PAZ and CCCH domains that is highly conserved in vertebrates. \n\n- Is preferentially and abundantly expressed in gonads (testis and ovary) during germ cell meiosis, suggesting it plays an important role in gametogenesis and RNA silencing in the germ line.\n\n- Has been characterized in sheep and mouse models, with mRNA transcripts of 4,803 bp and 4,962 bp respectively, encoding putative proteins of 1,600 and 1,653 amino acids. \n\nSo in summary, TOPAZ1 is a gonad-specific protein involved in germ cell development and meiosis."
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "response": "Unfortunately, the given information does not directly state which gene controls the expression of GATA-1 isoforms. The passage focuses on how the transcription factor GATA-1 regulates expression of the CCR3 gene through binding to multiple GATA sites within regulatory sequences of the CCR3 gene. It does not provide information on what controls expression of GATA-1 itself or its isoforms. The passage suggests that levels of endogenous GATA-1 affect its transcriptional activity on target genes like CCR3, but does not specify the specific gene(s) responsible for controlling GATA-1 expression. Based on the information provided, there is insufficient detail to definitively state which gene controls GATA-1 isoform expression. However, regulation of GATA-1 expression and alternative splicing likely involves complex interactions between multiple transcription factors and regulatory elements that are not elaborated on here in the context of describing GATA-1's regulation of the CCR3 gene."
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "response": "MIRA-seq stands for Massively Parallel RNA Sequencing. It is a method used to sequence RNA from a sample in order to analyze gene expression. \n\nSome key points about MIRA-seq:\n\n- It is a high-throughput sequencing method that allows the sequencing of millions of small RNA molecules or cDNA fragments in parallel. This provides a comprehensive profile of the transcriptome (all RNA transcripts) in a sample.\n\n- It can be used to quantify gene expression levels by counting the number of RNA reads that map to each gene. This allows differential expression analysis between samples (e.g. treatment vs control).\n\n- Compared to microarrays, it provides a wider dynamic range for quantifying expression levels (can detect very high and very low abundance transcripts). \n\n- It also allows the detection of novel transcripts, splice variants, rare transcripts, small non-coding RNAs etc. that may be missed by microarray methods.\n\n- However, MIRA-seq produces shorter sequence reads that may be more difficult to map to reference genomes compared to other sequencing methods. Bioinformatic analyses are required to process MIRA-seq data.\n\nSo in summary, MIRA-seq utilizes high-throughput next generation sequencing to get a snapshot of the transcriptome and gene expression profile in a sample. It is a powerful tool for transcriptomics research. The definition provided about SEQ does not seem directly related to explaining what MIRA-seq is."
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "response": "Unfortunately, there is no indication of ARCALYST in the given document. The document discusses the findings of a study investigating the inhibition profile of arctiin and arctigenin, which are compounds found in Fructus Arctii (the fruit of the Arctium lappa plant). Specifically, the study examined the inhibition of UDP-glucuronosyltransferases (UGT) enzymes by arctiin and arctigenin. The inhibition data were used to determine the possibility of herb-drug interactions with Fructus Arctii. The document does not mention ARCALYST or provide any information about its approved clinical indications. Based on the content provided, I do not have enough context to provide the indication for ARCALYST. Please provide more background information or details if you would like me to elaborate further on the indication of ARCALYST."
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "response": "Based on the information provided, the human acrocentric chromosomes that are involved in Robertsonian translocation described in this case are:\n\n- Chromosome 13\n- Chromosome 15\n\nSpecifically, the document mentions a Robertsonian translocation between chromosomes 13 and 15, with the breakpoints being 13q11 and 15p12. So chromosomes 13 and 15, which are acrocentric chromosomes in humans, underwent a Robertsonian translocation in the leukemia cells of the patient described."
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "response": "Based on the information provided, the R package that could be used for the identification/classification of pediatric brain tumors is the MethPed package.\n\nSpecifically, the background states that the MethPed R package implements a random forest classifier called the \"MethPed classifier\" that is able to diagnose and subgroup pediatric brain tumors based on their DNA methylation profiles. \n\nThe results then state that this MethPed R package can estimate the probability that an unknown sample belongs to one of nine pediatric brain tumor subgroups/diagnoses.\n\nFinally, the conclusions reiterate that the MethPed R package can efficiently classify pediatric brain tumors using this MethPed classifier that was developed.\n\nSo in summary, the MethPed R package available on Bioconductor would be an appropriate package that provides functionality for pediatric brain tumor identification and classification."
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "response": "Unfortunately, the passage does not clearly state whether NEMO is a zinc finger protein or not. The passage discusses N-ethylmaleimide (NEM), which is a chemical that can inactivate HIV and SIV viruses by alkylating the cysteine residues in zinc finger motifs of the viral nucleocapsid (NC) proteins. However, NEMO is not mentioned in the passage. The passage talks about how NEM treatment modifies the NC protein and other internal viral proteins, disrupting zinc finger structures that are important for viral infectivity and replication. But there is no information provided about NEMO or whether NEMO itself contains any zinc finger motifs. So based on the information given, it is unclear if NEMO is a zinc finger protein or not. The passage does not provide enough evidence to definitively answer the question asked."
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "response": "Unfortunately the given information does not explicitly state whether TFIIS affects nucleosome positioning or not. The document discusses the roles of ISWI chromatin remodeling factors and Tup1 in nucleosome positioning at the RNR3 gene, but does not mention TFIIS. TFIIS is involved in transcriptional elongation by RNA polymerase II rather than chromatin remodeling or nucleosome positioning. So from the information provided, it remains unclear what effect, if any, TFIIS has on nucleosome positioning. Without more context or supporting evidence regarding TFIIS, I cannot definitively state whether it affects nucleosome positioning based on this document. Perhaps examining other sources on TFIIS and its molecular functions would shed more light on this specific question. But the given information alone does not seem sufficient to determine if TFIIS influences nucleosome positioning at RNR3 or other genomic loci."
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "response": "Based on the information in the passage, origins of replication close to yeast centromeres fire early rather than late.\n\nThe key evidence supporting this is:\n\n1) The passage states that \"The centromeric regions of all Saccharomyces cerevisiae chromosomes are found in early replicating domains.\" This suggests origins near centromeres replicate early.\n\n2) The experiment described shows that when a functional centromere is moved near origins that normally reside in a late replicating region, it causes those origins to fire earlier. This demonstrates that centromeres push nearby origins into earlier replication.\n\n3) The conclusion states that \"a functional centromere acts in cis over a distance as great as 19 kb to advance the initiation time of origins.\" So the centromere causes earlier origin firing up to 19 kb away.\n\nSo in summary, the passage clearly supports the idea that origins near yeast centromeres tend to fire early due to the influence of the centromere region."
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "response": "From the passage, key properties of mammalian GA-sequences can be summarized as:\n\n1) GA-sequences, also called GABA(A) receptors, belong to the ligand-gated ion channels superfamily and play a key role in regulating behavior. \n\n2) They are highly diverse and prediction from amino acid sequences is useful for research. \n\n3) Derived features such as hydrophobicity, hydrophilicity, side chain mass, pK1, pK2 and pI values or combinations of these are useful for prediction using Chou's pseudo-amino acid composition and support vector machine.  \n\n4) Biologically justifiable rankings of attributes include pk2 and pI; hydrophobicity, hydrophilicity and mass; mass and pk1; pk2 and mass.\n\n5) Using Chou's pseudo-amino acid composition and SVM is an effective approach for predicting GABA(A) receptors from sequence.\n\nSo the key properties are: diversity, importance in regulating behavior, certain physicochemical features of amino acids for prediction, and utility of sequence-based prediction methods like Chou's pseudo-amino acid composition with SVM for studying these receptors."
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "response": "Unfortunately, the given information does not clearly state how many Groucho-related genes (GRG) are contained in the mouse genome. The text discusses the expression patterns of avian homologues of Groucho-related genes, including Grg1, Grg2, Grg3, Grg4, and Grg5/AES, during embryonic development in chickens. However, it does not specify the number of Groucho-related genes found in mice or any other organism. Without more context about the mouse genome specifically, I do not have enough information to definitively state how many GRG genes are present. The passage is focused on examining GRG gene expression in chickens, but does not provide clear data to answer the question about mouse GRG genes. I apologize that I cannot provide a more specific answer based on the information given. Let me know if you have any other questions!"
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "response": "Unfortunately, the question does not provide enough information to definitively state which RNA polymerase II subunit carries RNA cleavage activity. The passage discusses RNA cleavage factors associated with RNA polymerases I and III, specifically the A12.2 subunit of Pol I and the C11 subunit of Pol III, which stimulate the cleavage activity of those polymerases. However, it does not mention a corresponding subunit for RNA polymerase II (Pol II). The passage notes that despite sequence divergence, cleavage factors for cellular RNA polymerases appear to share a common mechanism of action through association with the polymerase secondary channel. But there is no specific information provided about a Pol II subunit responsible for RNA cleavage. Without more context about the subunits and domains of Pol II, I cannot confidently name which one, if any, carries inherent RNA cleavage activity based on the information given. The passage seems to suggest this may be a common feature of cellular RNA polymerases, but does not confirm it for Pol II."
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "response": "Based on the document, there is no mention of the genetic basis of Ohdo syndrome. The document discusses various pigmentary disorders and their genetic causes, such as:\n\n- Oculocutaneous albinism (OCA) types 1, 2, and 3 - caused by mutations in the tyrosinase, P protein, and DHICA oxidase genes, respectively. \n\n- Hermansky-Pudlak syndrome (HPS) - caused by mutations in the recently isolated and cloned HPS gene.\n\n- Chediak-Higashi syndrome (CHS) - caused by mutations in the recently isolated and cloned CHS gene. \n\n- Waardenburg syndrome (WS) types 1, 2, 3, and 4 - caused by mutations in the PAX3, MITF, c-kit, endothelin-3, or endothelin receptor B genes.\n\nIt also discusses dyschromatosis symmetrica hereditaria (DSH), but states that the disease gene and chromosomal localization have not been identified yet. There is no mention of the genetic basis or cause of Ohdo syndrome specifically. Based on the information provided, I do not have enough knowledge to provide the genetic basis of Ohdo syndrome. The document focuses on other pigmentary disorders."
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "response": "Unfortunately none of the documents provided explicitly mention a R/Bioconductor package developed specifically for the analysis of psychiatric disease genes. \n\nThe first document talks about the R453Plus1Toolbox, which is an R/Bioconductor package for the analysis of 454 sequencing data. It allows importing Roche sequencing projects into R and provides methods for quality assurance, annotation, and detection of variants and structural variants. It does not mention anything related to psychiatric disease gene analysis.\n\nSince there is no information provided that answers the question, I do not have enough context to provide a reasonable response about an R/Bioconductor package for psychiatric disease gene analysis. I would need documents that mention packages related to psychiatric disease genetics in order to formulate an appropriate reply based on evidence."
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "response": "Here is a summary describing the swirl sign in intracerebral hemorrhage:\n\nThe \"swirl sign\" refers to a characteristic imaging finding that may be seen on CT scans of patients with traumatic intracerebral hemorrhage (bleeding within the brain tissue). It consists of two components:\n\n1) A central area of hypoattenuation (low density) representing ongoing, active bleeding \n\n2) A peripheral, curved area of hyperattenuation (high density) representing clotted blood\n\nTogether these areas create a \"swirled\" pattern of alternating high and low density on the CT scan. This sign indicates that there is expanding bleeding within the brain which warrants urgent surgical intervention to evacuate the hematoma and stop the bleeding.\n\nEarly identification of the swirl sign is important as it indicates a risk of rapid neurological deterioration from the expanding hemorrhage. Aggressive and timely surgical management guided by the presence of this sign on imaging aims to improve patient prognosis and survival.\n\nIn summary, the swirl sign is an important CT imaging marker of traumatic intracerebral hemorrhage requiring urgent surgical management. Its recognition can guide critical and potentially life-saving treatment decisions."
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "response": "Unfortunately, the passages do not directly state what induces Arabidopsis ROF1 expression. The passages discuss the roles of ROP1, ROP6, and other related proteins in Arabidopsis, but do not specifically mention ROF1 or what induces its expression. \n\nThe passages talk about how Piriformospora indica (a root-colonizing fungus) stimulates the expression of the calmodulin-binding protein gene Cbp60g in Arabidopsis roots, and that this response is reduced in rop1 and rop6 mutant plants. However, ROF1 is not mentioned.\n\nSo based on the information provided, there does not seem to be enough detail to determine what specifically induces ROF1 expression in Arabidopsis. The passages focus more on ROP1, ROP6 and their roles related to the plant's interaction with P. indica. Hopefully this provides some clarification on what information is and is not provided regarding ROF1 and its expression. Let me know if you need any other details!"
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "response": "Based on the information provided, the most common cause of hereditary renal amyloidosis described in the passage is amyloidosis derived from the apolipoprotein C-II (Apo-CII) protein, caused by a specific mutation (E69V) in the APOC2 gene. The passage indicates that this is a newly discovered form of hereditary amyloidosis, termed \"AApoCII\", that appears to preferentially affect the kidneys in elderly patients. So in summary, the protein implicated as causing this hereditary renal amyloidosis is Apo-CII with the E69V mutation."
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "response": "Based on the information provided, it does not appear that the proteome of mice hippocampus has been analyzed. The passage states that a comprehensive proteome analysis of the hippocampus has not yet been accomplished, and describes a proteomics study that analyzed the hippocampus proteome of rats, not mice. Specifically:\n\n- It states \"A comprehensive analysis of the hippocampus proteome has not been accomplished yet.\" This suggests a full proteome analysis of the hippocampus, without specifying the species, has not been done.\n\n- It then describes a proteomics study where \"Hippocampus samples from eight months old animals were analyzed by two-dimensional electrophoresis and the proteins were identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.\" \n\n- The study constructed a protein database for \"rat brain hippocampus proteins.\" Rats and mice are different species, so this study analyzed the rat hippocampus proteome, not mice.\n\nSince the passage does not mention any analysis targeted specifically at characterizing the proteome of mice hippocampus, I would conclude the evidence suggests this has not been done yet based on the information provided. The proteome of rat hippocampus has been examined, but not yet the mice hippocampus proteome."
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "response": "Based on the information in the document, it seems that the Y chromosome in Apodemus agrarius mice is described as a medium-size acrocentric chromosome consisting of heterochromatin. So for Apodemus agrarius mice specifically, the answer is yes, the Y chromosome is acrocentric.\n\nThe document does not appear to provide clear information on whether all mouse chromosomes are acrocentric. It discusses polymorphisms and variability in the karyotypes and chromosome morphology of different Apodemus agrarius populations. But it does not definitively state that all mouse chromosomes are acrocentric across all species or populations. \n\nSo in summary:\n\n- The Y chromosome of Apodemus agrarius mice is described as an acrocentric chromosome\n\n- For other mouse chromosomes or other mouse species, the information is not definitive on whether they are acrocentric or not. There appears to be polymorphism and variability.\n\nTherefore, while the Y chromosome of Apodemus agrarius mice is acrocentric, the document does not provide enough information to determine if all mouse chromosomes in general are acrocentric. More definitive information seems needed to make that generalization. The document focuses specifically on the acrocentric nature of the Apodemus agrarius Y chromosome."
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "response": "Unfortunately, the provided text does not mention any specific siRNA based drugs that are in clinical trials for pancreatic cancer. The text discusses four studies on second line treatment options for pancreatic cancer that were presented at the 2012 ASCO Annual Meeting:\n\n1) A phase II study of the maintenance therapy sunitinib after first line treatment. Sunitinib is a small molecule kinase inhibitor drug.\n\n2) A phase I/II study of trabedersen, which inhibits TGF-beta 2 expression. This is an antisense oligonucleotide drug.\n\n3) Studies examining combining the small molecule kinase inhibitor lapatinib with either FOLFOX or capecitabine in second line treatment.\n\nHowever, none of these drugs are siRNA (small interfering RNA) based. The text does not provide any information about siRNA drugs in clinical trials for pancreatic cancer. Based on the information given, I cannot identify a specific siRNA based drug that is in clinical trials for this indication. Please let me know if you need any clarification or have additional information to provide."
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "response": "Based on the background information provided, the HPG pore refers to a toolkit called \"HPG Pore\" that is designed for exploring and analyzing nanopore sequencing data. Some key points about the HPG pore/HPG Pore:\n\n- It is a software toolkit for working with data from nanopore DNA sequencers like the MinION device made by Oxford Nanopore Technologies. Nanopore sequencing allows for sequencing of long fragments of DNA in real-time without amplification.\n\n- HPG Pore is designed to be scalable to handle the large amounts of data expected from extensive future use of nanopore DNA sequencing technologies. It can run on individual computers or in the Hadoop distributed computing framework.\n\n- It aims to provide a data analysis solution for nanopore sequencing data that goes beyond what's currently available, which can only manage small projects and doesn't scale well. \n\n- HPG Pore supports virtually unlimited sequencing data scalability to ensure it can manage future scenarios with exponential growth of nanopore sequencing data.\n\nSo in summary, the HPG pore refers specifically to the toolkit HPG Pore, which is designed for scalable analysis of nanopore sequencing data from devices like the Oxford Nanopore MinION."
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "response": "Based on the document, the 959 Nematode Genomes initiative is not directly mentioned. The document discusses using genome skimming and high-throughput sequencing approaches to assemble the first complete mitochondrial genome sequence of the root-knot nematode Meloidogyne graminicola. \n\nKey points about the document:\n\n- Uses genome skimming on Illumina HiSeq data to assemble the mitochondrial genome of the nematode Meloidogyne graminicola.\n\n- The assembled genome is 20,030 bp, AT-rich (84.3%), with 36 genes identified. \n\n- Compares the M. graminicola mitochondrial genome to other nematode mitochondrial genomes like M. javanica and M. hapla.\n\n- Points out the utility of next generation sequencing approaches for assembling complete nematode mitochondrial genomes for purposes like species identification, phylogenetics, and population genetics.\n\nThere is no direct mention of the \"959 Nematode Genomes initiative\" specifically in this document. The document focuses narrowly on using genome sequencing to assemble the mitochondrial genome of one nematode species, Meloidogyne graminicola. Hopefully this provides some helpful context regarding the content and what is not covered regarding any reference to 959 nematode genome sequences. Let me know if you need any clarification or have additional questions!"
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "response": "Unfortunately, the given information does not specify which R package has been developed specifically for analyzing non-invasive prenatal testing (NIPT) data. However, based on the context that the information discusses data collected from over 400 NIPT results, and the desire to present data and analysis, some R packages that may be useful for handling NIPT data include:\n\n- tidyverse - a suite of packages like `dplyr`, `ggplot2`, etc. that provide tools for data manipulation, visualization and analysis which could be applied to NIPT data.\n\n- pRoloc - a bioinformatics package for profile annotation and visualization of protein cellular localization. May be useful if analyzing protein markers from NIPT. \n\n- ROCit - an R package for calculating and visualizing Receiver Operator Characteristic (ROC) curves. Could be used for analyzinig NIPT classifier/risk scoring models.\n\n- survminer - R package for survival analysis and visualization (e.g. Kaplan-Meier curves). May be helpful if looking at outcomes over time based on NIPT results.\n\nSo while there does not seem to be one specific R package just for NIPT data, there are versatile packages that provide applicable tools for data wrangling, analysis and visualization that could be applied to these types of genomic datasets and research questions involving NIPT results. Let me know if you have any other questions!"
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "response": "Achenbach's syndrome is a rare condition characterized by recurrent bruising or blue discoloration of the fingers after minor trauma. Key features include:\n\n- Occurs suddenly after minor injuries to the hands and fingers such as bumping into objects. The bruising or blue discoloration is out of proportion to the degree of trauma.\n\n- Primarily affects middle-aged women.\n\n- The fingers are tender and painful when the bruising and discoloration occurs.\n\n- The episodes are transient, with the bruising and pain resolving spontaneously within hours to days without treatment.\n\n- There is no underlying vascular or coagulation defect - it is a diagnosis of exclusion when tests are normal.\n\n- The cause is unknown but speculated to be a transient vasospasm or hypersensitivity reaction of small blood vessels in the fingers. \n\n- Prognosis is good as the syndrome is benign and self-limited without any permanent injury to the fingers.\n\nIn summary, Achenbach’s syndrome is characterized by sudden, painful finger bruising after trivial injuries in middle-aged women. The episodes are transient and tests are normal. Reassurance is provided as no treatment is required."
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "response": "Unfortunately the document provided does not clearly state which algorithm is used for detection of long repeat expansions. It mentions that the method presented involves two steps - seed detection followed by their extension to detect approximate repeats. \n\nSome key points from the document:\n\n- It presents an implementation of a two-step method to detect approximate repeats in large DNA sequences. The steps are:\n  1. Seed detection\n  2. Extension of seeds to detect approximate repeats\n\n- The method allows for weighted substitutions and indels to detect approximate repeats, not just strict repeats. \n\n- It handles sequence-composition biases at both the seed detection and alignment levels.\n\n- The method is computationally efficient to handle large sequences.\n\nSo in summary, while it provides details on the overall approach and methodology, the document does not specify the actual algorithm or algorithms used to implement the two-step approximate repeat detection process. I do not have additional knowledge about which specific algorithms are typically used for this task. Please let me know if you need any clarification or have additional details to provide."
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "response": "Based on the information in the document, neuroligin-3 (NLGN3) promotes the growth of several types of high-grade gliomas, including:\n\n- Adult and paediatric glioblastoma (GBM)\n- Anaplastic oligodendroglioma  \n- Diffuse intrinsic pontine glioma (DIPG)\n\nThe document states that an important mechanism that mediates the neural regulation of these types of brain cancers is activity-dependent cleavage and secretion of the synaptic adhesion molecule neuroligin-3 (NLGN3). Specifically, secreted NLGN3 promotes glioma proliferation through the PI3K-mTOR pathway. \n\nTherefore, according to the passage, neuroligin-3 promotes the growth of adult and paediatric glioblastoma, anaplastic oligodendroglioma, and diffuse intrinsic pontine glioma."
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "response": "Based on the information provided, some details about the size of gas vesicles can be summarized:\n\n- Gas vesicles are formed by a protein called 'gas-vesicle protein' (GVP). \n\n- The GVP protein from the cyanobacterium Anabaena flos-aquae is 70 amino acids long and has a molecular weight (Mr) of 7,388 Da.\n\n- X-ray crystallography shows the repeating unit cell of intact gas vesicles corresponds to the size of this 7.4 kDa GVP protein.\n\n- So the approximate size of an individual gas vesicle structural unit is around 7-8 kDa, based on the size of the GVP building block protein. \n\n- However, GVPs can form various stable oligomers, suggesting multiple GVP subunits assemble to form the complete gas vesicle structures. \n\nSo in summary, gas vesicles are comprised of 7-8 kDa GVP protein subunits that oligomerize together into the complete gas vesicle structures, but an exact overall size is not clearly specified from the information provided. Let me know if you need any clarification or have additional questions!"
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "response": "Based on the information provided, some BET proteins that can be listed are:\n\n- BRD2\n- BRD3 \n- BRD4\n\nThese BET bromodomain-containing proteins are mentioned in the document as targets for small-molecule inhibitors like compound 18. Specifically, the document states that compound 18 binds to BRD2, BRD3, and BRD4 proteins with high affinity. Therefore, BRD2, BRD3, and BRD4 are key BET proteins highlighted in this context."
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "response": "Based on the information provided, the algorithm that has been developed for prediction of protein subcellular localization using deep learning is described here:\n\nThe core of the prediction model is a recurrent neural network that processes the entire protein sequence and uses an attention mechanism to identify protein regions important for the subcellular localization. This deep neural network algorithm relies only on protein sequence information to make predictions. It does not rely on annotation of homologues from knowledge databases.\n\nThe model was trained and tested on a curated UniProt protein dataset. It demonstrates good accuracy (78% for 10 localization categories; 92% for membrane-bound vs soluble). The web server providing this prediction method is available at http://www.cbs.dtu.dk/services/DeepLoc, and the code is available at https://github.com/JJAlmagro/subcellular_localization.\n\nSo in summary, the deep learning algorithm utilizing recurrent neural networks and attention mechanism, developed by the DTU group and presented in the provided background, is the method developed for prediction of protein subcellular localization based purely on sequence data."
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "response": "Based on the information provided, MULTOVL is not explicitly defined. The document discusses Pasteurella multocida, which is a type of bacteria that can cause disease in humans and animals. Some key points about Pasteurella multocida from the document:\n\n- It is a gram-negative bacillus (rod-shaped bacterium) found in many farm and domestic animals. Common carriers include swine and poultry.\n\n- It can be transmitted to humans through animal bites, scratches, or other contact with saliva from infected animals. This is considered a zoonotic infection (spread from animals to humans). \n\n- The document mentions a case where Pasteurella multocida was transmitted by cooking pig trotters, representing a previously unknown transmission route. \n\n- It is associated with a range of diseases in humans, including wound infections, respiratory infections, and septicemia. The severity can vary widely.\n\nSo in summary, MULTOVL is not defined in the given information. The document focuses on discussing Pasteurella multocida bacteria and respiratory infections caused by exposure during cooking of pig parts. Let me know if you need any clarification or have additional questions!"
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "response": "Based on the background information provided, there is no clear evidence to suggest that GDF15 can be used as a biomarker for metformin treatment specifically. Here are a few key points:\n\n1) The document discusses using GDF15 as a general biomarker in various disease settings, including cardiovascular disease. It does not mention metformin treatment. \n\n2) The study focused on developing an assay to measure GDF15 levels and establishing reference ranges in healthy elderly individuals and heart failure patients. It did not evaluate GDF15 levels before/after any treatments.\n\n3) The conclusion states that the favorable characteristics of GDF15 are expected to facilitate future studies of its use as a biomarker in various disease settings. But again, no link to metformin is made.\n\nSo in summary, while GDF15 shows promise as a general biomarker, more research would be needed to specifically evaluate whether it could serve as a marker for metformin treatment response or outcomes. The provided background does not directly address this question. Additional interventional studies looking at GDF15 levels with metformin use would be helpful to establish this."
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "response": "Based on the information in the document, there is no clear evidence that recursive splicing is more common in short introns. The key points related to intron length are:\n\n- Recursive splice sites predicted with highly stringent criteria are found at much higher frequency than expected in the sense strands of introns >20 kb, but they are underrepresented within introns <10 kb.\n\n- Mutation of a recursive splice site within a shortened version of a large intron did not change the predominant processing pathway. Recursive splicing was still the predominant way this intron was removed.\n\nSo introns under 10kb have fewer recursive splice sites than expected, indicating recursive splicing is less common in short introns. While long introns (>20kb) frequently use recursive splicing as the predominant processing pathway even with shortened lengths, suggesting this is the standard way very long introns are processed.\n\nSo recursive splicing appears more common in long introns compared to short ones based on the evidence in the document. There is no indication recursive splicing is more common in short introns."
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "response": "Based on the information provided, it seems the TALE-iD method refers to using transcription activator-like effectors (TALEs) as programmable DNA binding proteins to target specific sequences in the genome. Specifically:\n\n- TALEs consist of multiple repeats, each repeat selectively recognizes one DNA nucleobase via a repeat variable diresidue (RVD).\n\n- The research studied the binding ability of TALEs to the modified nucleobase N6-methyladenine (6mA). \n\n- They found the natural adenine-binding RVD NI is insensitive to 6mA. Through structure-function studies, they identified RVDs that can accommodate and bind to 6mA and other bulkier modifications at the N6 position of adenine.\n\n- This tolerance of modifications at the N6 position enables introduction of labels like alkynyl groups or rhodamine dyes within TALE binding sites, without interfering with TALE binding.\n\nSo in summary, the TALE-iD method seems to refer to an approach to introduce chemical modifications or bulk labels at the N6 position of adenines within TALE binding sites in the genome, while preserving TALE binding ability. This expands the applicability of TALEs as programmable DNA binding proteins for genome targeting and analytical applications."
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "response": "Unfortunately, the passages provided do not mention any specific Lisp framework developed for image processing. The first passage discusses putting forward an image rendering system based on a pipeline framework, but does not specify if this framework is based on Lisp or identify it as a Lisp framework. The passage seems to be focused more on the capabilities of the system rather than the underlying implementation. \n\nThe second passage also does not mention anything about Lisp or a Lisp framework. It discusses implementing various image processing techniques in a PACS image system, but provides no details on the software infrastructure or frameworks used.\n\nSince neither passage refers to a Lisp framework for image processing, I do not have enough information to definitively name one that has been developed for that purpose based on the provided documents. My knowledge outside these passages on this specific question is limited. I apologize that I could not provide a more useful response identifying a relevant Lisp image processing framework here. Let me know if you need any clarification or have additional information to share that could help identify an applicable framework."
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "response": "Based on the information in the passage, it does not explicitly state the exact number of genes in S. cerevisiae that are the result of an ancient whole genome duplication. However, some key details related to this are provided:\n\n1) A whole-genome duplication occurred in the ancestor of Saccharomyces yeast species. This suggests many genes originated from this duplication event.\n\n2) 92% of the duplicates from this event returned to single-copy genes shortly after the duplication. So only 8% of duplicates were retained. \n\n3) The passage states that the preserved duplicated genes led to metabolic innovations, indicating some number were retained. But an exact number is not provided.\n\nSo while the passage discusses the ancient whole genome duplication and its effects, there is no clear statement on the precise number of current S. cerevisiae genes originating from that event. The key points are many duplicates initially resulted from the duplication, but most were lost, leaving an unspecified portion that led to innovations. But the exact statistic requested in the original question is not clearly specified based on the information given."
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "response": "Unfortunately, the given document does not provide clear information to answer the specific question: Which complex is bound by estrogen-related receptor β (Esrrb)?\n\nIt describes research on the binding interactions between various estrogen receptor (ER) complexes (without or with different agonists/antagonists bound) and different estrogen responsive elements (EREs) from the vitellogenin A2 gene and PS2 gene. However, there is no mention of estrogen-related receptor β (Esrrb) or which complex is bound by it. \n\nSince the document does not contain information to answer that specific question about Esrrb, I do not have enough information to provide a reasonable response. The passage is focused on characterizing the binding of ER to EREs under various conditions. If additional details are provided about Esrrb and what specific information is sought, I would be happy to try to provide a better response. Please let me know if you have any other questions!"
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "response": "Unfortunately, the provided document does not mention the specific role of ZCCHC17. It discusses the role of a related protein called Zcchc11 in regulating cell proliferation and the cell cycle, but does not provide any information about ZCCHC17. The document indicates that Zcchc11 promotes the G1 to S phase transition in the cell cycle through both Rb-dependent and Rb-independent mechanisms. It also suggests the N-terminal region of Zcchc11 is important for facilitating cell proliferation. However, without additional context or documents discussing ZCCHC17, I do not have enough information to definitively state the role of ZCCHC17. Based on the information provided, the specific function of ZCCHC17 remains unclear. Please provide more background information or source documents discussing ZCCHC17 if you would like me to describe its particular role."
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "response": "Based on the document, the proteins that form the nuclear pore basket in human cells are not definitively stated. The document discusses research related to the nuclear pore basket in yeast cells, specifically mentioning the yeast proteins Nup60 and Mlp1 as nuclear basket components. \n\nThe document also notes that in yeast, Esc1 is required for proper assembly of the nuclear basket. However, the key point is that this research is focused on yeast cells, not human cells. No specific proteins are named as components of the nuclear pore basket in humans. \n\nTo summarize, while this research provides insights into the nuclear pore basket in yeast, it does not clearly identify which proteins form the nuclear pore basket in human cells. Further information or research focused specifically on human cells would be needed to answer that question. The document provides background information related to the nuclear pore complex but does not directly address the question about basket proteins in human cells."
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "response": "Based on the information in the document, gepotidacin is not explicitly described as a specific type of topoisomerase inhibitor. The document indicates that gepotidacin is a novel triazaacenaphthylene antibacterial being evaluated for the treatment of uncomplicated urogenital gonorrhea. It discusses microbiological correlates of successful treatment with gepotidacin, including the association between the ratio of the area under the free-drug concentration-time curve to the MIC (fAUC/MIC) and therapeutic success. The document also notes the emergence of resistance to gepotidacin in some isolates due to mutations in GyrA at residue A92, a residue implicated in gepotidacin binding, suggesting gepotidacin may interact with gyrase/topoisomerase. However, the specific mechanism or type of topoisomerase inhibition is not stated. Based on the information provided, a definitive classification of gepotidacin as a certain type of topoisomerase inhibitor cannot be made."
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "response": "Here is a summary of the key points about the sludge cellulose plastic composite (SPC) presented in the paper:\n\n1. The paper develops a novel SPC material in line with the circular economy concept, using recovered cellulose from wastewater treatment plant sludge. This aims to replace wood in traditional wood plastic composites (WPC).  \n\n2. WPC was also developed in parallel, to determine the comparative properties and substitution potentials versus SPC.  \n\n3. Maleic anhydride (MA) and vinyltrimethoxysilane (VTMS) coupling agents were used to improve the interfacial bonding in both SPC and WPC.  \n\n4. Mechanical testing showed improved tensile and flexural strength for both SPC and WPC after MA and VTMS treatment, with MA being more efficient.\n\n5. SEM analysis confirmed better embedding and bonding of the cellulose/wood flour in the plastic matrix with the coupling agent treatments.  \n\n6. WPC had slightly better thermal stability, but SPC showed comparable flexural properties.\n\n7. Eco-efficiency assessment suggested SPC has superior environmental and economic performance over WPC.\n\n8. The replacement of wood flour with recovered sludge cellulose for plastic composites production helps enable a circular economy approach.\n\n9. The results position sludge cellulose as a promising sustainable alternative to wood for WPC manufacturing."
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "response": "Unfortunately I do not have enough context to provide a list of STING agonists. A STING agonist refers to a substance that activates STING (stimulator of interferon genes) which is involved in innate immunity. Without more details on the context in which you are looking for STING agonists, I cannot reasonably provide a list. Please provide some additional background information or details on why you are asking for this list. I'd be happy to try to provide a more helpful response with some additional context."
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "response": "Based on the information provided, here is a description of some key points about the SLIC-CAGE document:\n\n- The scanning liquid-filled ionization chamber (SLIC) electronic portal imaging device has had its dosimetric characteristics investigated. This includes obtaining characteristic curves across various field sizes and photon beam energies of 6 and 10 MV.\n\n- The SLIC system's response is dependent on the intensity of the incident radiation beam. Its central axis response can be described to within 1% accuracy using a square root function.  \n\n- Homogeneous phantom measurements show the SLIC can measure portal (transmission) doses on central axis to within 3% accuracy compared to ionization chamber results. \n\n- For 2D dosimetry, the system is calibrated using a 10 cm Perspex block as a flattener on the detector cassette. This corrects for variations in individual ion chamber sensitivity and nonuniform beam profiles from the flattening filter.  \n\n- Open and wedged dose profiles agreed with separately measured ion chamber profiles to within 3.5% accuracy after the calibration and corrections were applied."
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "response": "Unfortunately I do not have enough context in the provided document to specifically determine the roles of LEM-3. The document does not mention LEM-3 or provide details about what that refers to. It discusses research related to leptin, the OB3 peptide, and their effects on ovarian cancer cell proliferation and signaling pathways. Specifically, it found that leptin stimulated proliferation in ovarian cancer cells while the OB3 peptide blocked that effect and disrupted some of leptin's signaling, suggesting OB3 could potentially prevent leptin-induced ovarian cancers. But there is no mention of LEM-3 or what roles it may play. Without more context about what LEM-3 refers to, I cannot provide specific details about its roles based on this document. I would need more background information about the meaning of LEM-3 in order to respond accurately. Please provide some clarification about what you are asking regarding LEM-3 and I'm happy to try to provide a more useful response."
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "response": "Based on the document, the releases of tmVar that are described are:\n\n1) Sustained release of TM (timolol maleate) from the silicone hydrogel contact lenses for 4 to 14 days. \n\n2) Noncovalent entrapment of the wetting agents PVP and HA (hyaluronic acid) did not change the in vitro release duration and kinetics of TM, though the release profile was controlled by the simultaneous release of TM and the wetting agents.\n\n3) With HA as the wetting agent, depending on the HA:drug ratio, the release rate of TM was decreased and controlled by the release of HA, likely due to electrostatic interactions between protonated TM and anionic HA.\n\nNo other specific tmVar releases are mentioned in the document. The releases listed focus on the release of the drug timolol maleate (TM) from the silicone hydrogel contact lens materials."
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "response": "Unfortunately, the given passage does not explicitly mention the database of somatic mutations in normal cells. The passage focuses on analyzing mitochondrial DNA (mtDNA) somatic mutations in breast cancer tissues and matched normal tissues. It reports the identification of two specific mtDNA mutations - T2275C and A8601G - in the primary cancerous and normal tissues of a few patients. However, it does not name or reference any databases of somatic mutations in normal cells. Without more context or relevant information provided, I do not have enough details to definitively state which database catalogs somatic mutations in normal cells. The passage is more centered on discussing observations from the specific study on mtDNA mutations in breast cancer rather than databases of mutations. Apologies that I could not directly answer the question, but in this case the information provided does not contain the answer. Please let me know if you have any other questions!"
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "response": "Based on the document provided, it does not directly state whether there are graph kernel libraries available implemented in Java. However, here is what I can infer:\n\nThe document talks about using graph-theoretic kernel methods and extending the tree pattern graph kernel to distinguish between stereoisomers. This suggests there are existing graph kernel methods being used.\n\nIt also mentions using these graph kernels with machine learning techniques like Support Vector Regression (SVR). \n\nSo while it does not explicitly confirm if there are Java libraries available, the use of graph kernels and machine learning algorithms implies there would be existing libraries and implementations available to facilitate this, potentially including Java options.\n\nHowever, without more direct confirmation in the document, I cannot definitively state whether Java graph kernel libraries exist. The document focuses more on describing a new proposed method rather than reviewing available libraries. Additional context would be needed to confirm available Java implementations.\n\nIn summary - the document suggests graph kernels are actively used in this domain but does not directly confirm existing Java libraries. More context would be helpful to state their availability definitively. I hope this provides some useful interpretation of the information given! Let me know if you need any clarification or have additional questions."
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "response": "Unfortunately, the given information does not clearly list four advances integrated into the SHERLOCKv2 platform. The passage discusses some advances related to an extension of the Java Molecular Viewer (JMV), such as:\n\n1) Adapting JMV to virtual reality display environments\n2) Overlaying phylogenetic information derived from multiple alignments onto molecule structures  \n3) Dynamically updating displayed information based on changes to the number of sequences in the underlying multiple alignment\n4) Handling an infinite number of objects (molecules) in the same display that can be manipulated simultaneously or independently\n\nHowever, these advances are for JMV rather than SHERLOCKv2 specifically. The passage does not provide enough information to list four distinct advances integrated into the SHERLOCKv2 platform. Without more context about SHERLOCKv2 and what capabilities or advances have been integrated into it, I unfortunately cannot provide a list of four as requested in the question. I would need more information about the SHERLOCKv2 platform and its specific integrated advances to comprehensively address this question."
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "response": "The bartender algorithm is a simple load balancing algorithm that distributes work among a set of servers, represented as \"bartenders\" in the analogy. When a job arrives, the algorithm chooses an available or idle server to assign the job to. If all servers are busy, the job gets added to a queue. When a server finishes its current job, it simply takes the next job from the queue, if there is one. This process repeats as new jobs arrive.\n\nSome key characteristics of the bartender algorithm are:\n\n- Simple implementation with a job queue and state checks on servers\n- Low overhead and fast job assignment when there are idle servers\n- Work is distributed evenly across servers in the long run \n- Can suffer from long queue length and waiting times if system is over-utilized\n\nThe bartender approach works well in basic scenarios with identical servers and independent jobs. More advanced load balancers may add features to account for heterogeneous servers, job priority, and communication overhead. But at its core, the bartender algorithm captures the basic idea of distributing incoming jobs across available resources."
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "response": "Based on the information provided, here are some web-based pedigree editors that are available:\n\n1. The novel web-based pedigree editor described in the passage. This tool was programmed in Java using a PHP interface, allows for generating, editing, and viewing complex pedigrees with unlimited generations and family members, minimizes storage space, and standardizes pedigree presentations. It is implemented with a TSHR mutation database.\n\n2. No other specific web-based pedigree editors are mentioned. However, the passage notes that this tool has advantages over existing tools, implying that other web-based pedigree editors exist. The details and names of other available editors are not provided though.\n\nIn summary, the key web-based pedigree editor highlighted is the novel Java/PHP-based tool discussed in detail in the passage. The passage also implies the existence of other web-based pedigree editors, though no specifics on those are provided."
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "response": "Based on the document, here are some curated databases that exist for spider-venom toxins:\n\n1. ArachnoServer - This database focuses specifically on spider toxins and provides information and annotations on these toxins.\n\n2. UniProtKB - While not spider-toxin specific, UniProtKB has an animal toxin annotation program that includes spider toxins among toxins from other venomous animals. So it contains curated data on spider toxins. \n\n3. ATDB (Animal Toxin Database) - This is described as a \"metadatabase\" that compiles data and annotations on animal toxins from other databases, including spider toxins. So it collects and curates spider toxin data from multiple sources into one database.\n\nIn summary, ArachnoServer, UniProtKB, and ATDB are three curated databases mentioned that have information on spider-venom toxins. Other databases may exist, but these are three that are specifically called out in the provided document as containing curated spider toxin data."
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "response": "Unfortunately, based on the information provided in the document, it does not clearly state whether Axitinib prolongs survival of pancreatic cancer patients. Some key points from the document:\n\n- Axitinib is an inhibitor of VEGF receptors that has been tested in clinical trials against various types of tumors, including pancreatic cancer. \n\n- The document discusses findings from key phase II clinical trials of Axitinib in various tumors, but does not provide specific data on overall survival benefits in pancreatic cancer.\n\n- Ongoing Phase III studies in pancreatic cancer should help determine the optimal use and benefits of Axitinib and other similar VEGF/VEGFR inhibiting agents.\n\nSo in summary, while Axitinib has been studied in pancreatic cancer patients, the available information does not definitively state whether it prolongs survival based on clinical trial evidence so far. Further Phase III study results would be needed to demonstrate any potential overall survival benefit specifically for pancreatic cancer patients treated with Axitinib."
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "response": "Unfortunately the document provided does not explicitly state through which protein interaction MLP regulates F-actin dynamics. The document discusses several ways in which MLP interacts with actin filaments, but does not specify which interaction is responsible for regulating F-actin dynamics:\n\n1) MLP autonomously binds to, stabilizes, and bundles actin filaments. This suggests MLP directly interacts with actin filaments, but the document does not state this interaction regulates F-actin dynamics.\n\n2) BiFC assays revealed MLP self-association, and the BiFC complexes localize along actin filament-rich structures. This suggests MLP interactions with itself may play a role in actin organization, but again does not explicitly state this regulates F-actin dynamics.  \n\n3) MLP self-associates through its N-terminal LIM domain and binds actin filaments through its C-terminal LIM domain. This describes the domains involved in self-association and actin binding but does not specify if either interaction regulates F-actin dynamics.\n\nSo in summary, while the document describes several MLP interactions, it does not explicitly state which of these interactions regulates F-actin dynamics. It discusses MLP's influence on actin organization overall, but does not specify the mechanism regulating F-actin dynamics in particular. Let me know if you need any clarification or have additional questions!"
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "response": "Unfortunately, the given text does not provide clear information to directly answer the specific question asked about how many pseudokinases are in the human kinome. The text discusses research related to the antigenicity of the main immunogenic region (MIR) on the acetylcholine receptor (AChR) alpha-subunit and binding of anti-MIR monoclonal antibodies to peptides from this region. It does not mention pseudokinases or provide any information about the number of pseudokinases in the human kinome. \n\nWithout additional relevant information to the specific question asked, I do not have enough context to provide a reasonable answer or estimate. I would either need clarification that this is the intended question, or additional background information related to pseudokinases and the human kinome to formulate an appropriate response. Please let me know if you can provide any clarification or additional information for me to better answer the question."
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "response": "Unfortunately I do not have enough context in the information you provided to list 3 specific apoE mimetics. The passage discusses the synthesis of a library of mimetics of the cyclic depsipeptide hapalosin, but does not mention apoE (apolipoprotein E) or provide examples of 3 apoE mimetics. If you could provide more background information related to apoE and mimetics of interest, I would be happy to try providing 3 examples. Please let me know if you can clarify the question or provide any additional details."
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "response": "Unfortunately, the given information does not specifically address sex differences in SAMHD1 activity. The passage discusses research on sex differences in daily fluctuations of hepatic cytochrome P450 monooxygenase activities in rats, as measured by 7-alkoxycoumarin O-dealkylase (ACD) activity. \n\nThe key points are:\n\n- Male rats showed daily fluctuations in ACD activity, with high values during the dark period, while female rats did not show an apparent daily fluctuation. This confirms a sex difference.\n\n- This sex difference appears to be influenced by differences in growth hormone secretion patterns between males and females. Mimicking the male pattern of growth hormone secretion in hypophysectomized female rats resulted in them showing a fluctuation in ACD activity similar to normal males.\n\nHowever, there is no mention of SAMHD1 or any data/conclusions relating to sex differences in SAMHD1 specifically. The passage is focused entirely on cytochrome P450 enzymes and growth hormone effects on ACD activity rhythms in the liver. Hopefully this helps summarize the provided information! Let me know if you need any clarification or have additional questions."
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "response": "Based on the information in the provided document, there is no evidence suggesting that RUNX2 inhibits astrocyte differentiation. The document discusses how changes in CDK2 and p27kip1 levels accompany the differentiation of CG-4 progenitor cells into astrocytes, and that an increase in p27 levels and decrease in CDK2 activity seem to promote astrocyte differentiation by preventing cell cycle progression. However, there is no mention of RUNX2 or its role in astrocyte differentiation. So from the given information, it is not possible to conclude whether RUNX2 inhibits astrocyte differentiation. The document simply does not provide relevant information to address this specific question. Additional documents discussing the role of RUNX2 in glial cell differentiation would be needed to determine if RUNX2 inhibits astrocyte differentiation. But based on Document 0 alone, there is no evidence to support that claim."
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "response": "Unfortunately, there is not enough information in the given document to determine where the Cobb-Stainsby excision arthroplasty is performed. There is no mention of the Cobb-Stainsby excision arthroplasty procedure in the provided document. The document discusses Cobb syndrome and surgical excision of a spinal arteriovenous malformation, but does not give any specifics on a Cobb-Stainsby excision arthroplasty procedure or where it would be performed.\n\nWithout more context or documentation about the Cobb-Stainsby excision arthroplasty procedure itself, I do not have enough information to provide a location in the body where this procedure would be performed. I apologize that I cannot provide a more helpful response given the provided information. Please let me know if you have any other questions!"
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "response": "Based on the information provided, it is unclear whether GRHL2 overexpression leads to EMT. The document discusses how LOXL2 overexpression induces EMT by activating the IRE1-XBP1 signaling pathway and upregulating certain EMT transcription factors. However, there is no mention of GRHL2 in the document. GRHL2 is not listed as one of the EMT transcription factors that are upregulated by LOXL2-induced IRE1-XBP1 signaling. Without any evidence linking GRHL2 overexpression to EMT induction, I cannot conclusively state whether GRHL2 overexpression leads to EMT based on the document provided. More information specifically examining the relationship between GRHL2 expression levels and EMT would be needed to determine if GRHL2 overexpression triggers EMT. The document focuses on the mechanism by which LOXL2 overexpression induces EMT, but does not explore the impact of GRHL2 levels on EMT."
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "response": "Unfortunately, the question does not provide enough information to definitively state which specific T-UCRs (transcribed ultraconserved regions) have been implicated in lung cancer. The passage discusses transcription factors like AHR and FOXJ1 that appear to become inactivated in lung cancer, as well as DNA methylation changes affecting the AHRR locus. However, it does not mention anything about T-UCRs or provide any examples of specific T-UCRs involved in lung cancer. \n\nWithout more context or background information provided in the question, I do not have sufficient information to name T-UCRs that play a role in lung cancer. The passage focuses more broadly on transcriptional and epigenetic changes in lung carcinogenesis, rather than any specific T-UCR involvement. If the intent was for me to extract T-UCR examples from the given background, unfortunately there is no mention of T-UCRs at all. Please provide more details or clarification if you were expecting me to provide specific T-UCR examples implicated in lung cancer based on this information. I'm happy to revisit my answer with any additional context you can provide."
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "response": "Based on the information provided, several key points are known about the orphan receptor GPR151:\n\n1) GPR151 is one of seven new members of the human G protein-coupled receptor (GPCR) superfamily identified through genome database searches. Along with 16 orthologues in mouse, rat, fugu, and zebrafish.\n\n2) Phylogenetic analysis shows GPR151 is an additional member of the rhodopsin-type GPCR family.\n\n3) GPR151 does not have any close relatives among other known human rhodopsin-like GPCRs. It is highly conserved through several vertebrate species and present in a single copy.\n\n4) No information is specifically provided about the expression pattern of GPR151 based on EST analysis. The document only mentions findings for GPR135 and GPR141 in this regard.\n\n5) As an orphan receptor, the endogenous ligand and signaling mechanisms of GPR151 are currently unknown. Additional study would be needed to elucidate the functional roles of this receptor.\n\nIn summary, GPR151 is a newly discovered, phylogenetically-related, yet highly novel member of the rhodopsin GPCR family that awaits further characterization of its biological significance. The available information about its expression profile and signaling properties remains very limited based on the passage provided."
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "response": "Unfortunately, the information provided does not list the specific attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine. \n\nThe document discusses a live-attenuated influenza vaccine (LAIV) delivered intranasally, but does not specify whether this refers to the Fluzone intradermal quadrivalent vaccine. Additionally, it focuses on evaluating aerosol delivery methods for an intranasal LAIV rather than listing the attenuated viruses it contains.\n\nFluzone intradermal quadrivalent is an inactivated influenza vaccine, meaning it does not contain any live viruses, attenuated or otherwise. Common attenuated live virus vaccines often contain weakened forms of measles, mumps, rubella, chickenpox or flu viruses. \n\nHowever, the document does not provide enough context to definitively state which, if any, attenuated viruses are present in the Fluzone intradermal quadrivalent vaccine. Based on the limited information provided, I do not have sufficient details to list the attenuated live viruses it contains. Please provide more specific information about the vaccine composition if you need additional details on which attenuated viruses it includes."
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "response": "Based on the information provided, there does not seem to be clear evidence that a specific part of the TNFR2 gene is genetically associated with systemic lupus erythematosus (SLE). The study examined the TNFR2 196 R/M polymorphism in exon 6 in Korean patients, but found no significant difference in genotype or allelic frequencies between SLE patients and healthy controls. The clinical characteristics of SLE were also not different according to the genotypes. \n\nThe passage states that while the TNFR2 gene locus on chromosome 1p36 encompasses a susceptible locus for SLE, and the ligand TNF is associated with SLE, this particular study did not find an association between the TNFR2 196 R/M polymorphism and SLE. It concludes that further studies in other populations are needed to elucidate if there is a role of TNFR2 polymorphisms in SLE development.\n\nSo in summary, the study does not provide evidence that a specific part of the TNFR2 gene is genetically associated with SLE. More research would be needed to determine if other variations or polymorphisms in the gene are associated with SLE susceptibility."
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "response": "Based on the information provided, there is currently no approved vaccine for peanut allergy. The study described tests an experimental peanut allergy immunotherapy using nanoparticles, but notes that there is no approved immunotherapy treatment available yet. Specifically, the background states \"there is currently no approved immunotherapy treatment\" for peanut allergy. While the nanoparticle formulation showed promising results in the mouse model by reducing anaphylactic symptoms, this is still at the experimental stage. The conclusion also does not state that a vaccine has been developed. So in summary, no, there is not currently an approved vaccine for peanut allergy based on this information. More research is still needed to develop and validate an effective immunotherapy that could potentially lead to an approved vaccine in the future."
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "response": "Unfortunately, the provided documents do not contain any information about the Fxy gene's chromosomal position or anything particularly unique about it. The documents discuss mapping of genes related to sex determination (Sxr, Tdy, Hya) to the short arm of the mouse Y chromosome. But there is no mention of the Fxy gene or its chromosomal location. Without any information provided about the Fxy gene specifically, I do not have enough context to provide a response detailing what might be unique or particular about its chromosomal position. Let me know if you have any other documents or background information to share related to the Fxy gene, as that would allow me to attempt to address your initial question."
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "response": "Based on the information in the document, the key basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method is:\n\nMPE.Fe(II) preferentially cleaves phosphodiester bonds in double-stranded regions of RNA molecules. The document shows this using the example of phenylalanine-accepting tRNA (tRNAPhe). It compares MPE.Fe(II) cleavage sites to those cleaved by cobra venom ribonuclease (a double-strand-specific endoribonuclease) and S1 nuclease (a single-strand-specific nuclease). There is correspondence between MPE.Fe(II) cleavage sites and the double-stranded regions sensitive to cobra venom ribonuclease, while there is less correspondence to single-stranded regions cleaved by S1 nuclease.\n\nTherefore, the basis of MPE-seq is that MPE.Fe(II) can preferentially cleave and probe double-stranded helical regions in an RNA molecule due to its small size allowing greater accessibility compared to bulkier enzymic probes. The cleavage sites can then be analyzed to map out the secondary structure of the RNA."
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "response": "Based on the information provided in the document, GCI (Graphics Command Interpreter) has been implemented using the C programming language. Specifically, the document states:\n\n\"The program is written in C and initially implemented using the Silicon Graphics GL graphics library.\"\n\nSo GCI, which seems to be the system referred to as GWAR in the original question, is written in C. Therefore, the programming language used to implement GWAR (or GCI) is C."
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "response": "Based on the information in the document, xaliproden does not clearly improve prognosis in ALS patients, but may have some potential benefit. Specifically:\n\n- The phase II study showed a trend favoring xaliproden over placebo in reducing rate of deterioration in functional scores like FVC, limbs functional score, and manual muscle testing score. However, these results were not statistically significant. \n\n- In patients who completed the analysis (\"completer analysis\"), there was a significant 43% slower decline in FVC with xaliproden treatment vs placebo (p=0.046). However, there was no significant effect in the other functional or muscle testing scores. \n\n- The authors conclude that xaliproden \"may have potential effects\" in ALS and \"deserves further study.\" However, they do not conclude that it clearly improves prognosis or has clear therapeutic effects based on this phase II trial. \n\nSo in summary, while xaliproden showed some potential signals of slowing disease progression in ALS patients, more evidence from larger or phase III trials would be needed to firmly establish whether it can improve prognosis or disease outcomes. This phase II study suggests potential promise, but does not firmly prove an improvement in ALS patient prognosis."
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "response": "Unfortunately, the given information does not clearly state which chromosome the transgenes are inserted into in the case of the LiPS-A3S line. The passage discusses the introduction and integration of transgenes in Dictyostelium discoideum in general, but does not mention the specific LiPS-A3S line or indicate which chromosome its transgenes would be inserted into. \n\nThe passage states that transformation vectors typically integrate into the genome at one or a few insertion sites as tandem arrays, and that exceptions are extrachromosomal vectors which do not integrate into chromosomes, and vectors with certain resistance markers which integrate as single copies. However, it does not specify which chromosome(s) the vectors integrate into.\n\nWithout more context about the LiPS-A3S line and its transgenes specifically, I do not have enough information to definitively state which chromosome they are inserted into. The passage discusses general integration patterns but does not provide chromosome details for this specific line. Perhaps clarification or additional background information on the LiPS-A3S line would help determine which chromosome its transgenes are inserted into. But based on the information provided, I cannot reasonably answer which chromosome they are inserted into."
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "response": "Based on the information provided, there is no clear mention of any specific tools that exist for predicting drug synergy with deep learning. The document describes using supervised machine learning to predict which drugs human cardiomyocytes have been exposed to, by training a model on electrophysiological data collected from cardiomyocytes with known drug exposures. However, it does not discuss predicting drug synergy.\n\nSome possibilities I can think of that may be relevant are:\n\n- Researchers could potentially train deep learning models on combination drug screening data to try to predict synergistic drug pairs. However, no specific tools designed for this are mentioned.\n\n- The techniques described in the document relate to predicting drug effects and exposures based on physiological data. Similar supervised learning approaches may be adaptable to predict drug synergy from phenotypic or bioassay data. But again, no out-of-the-box tools are referenced.\n\nIn summary, while the provided information demonstrates using machine learning to categorize drug effects, it does not clearly mention any existing tools leveraging deep learning specifically for predicting drug synergy. New techniques would likely need to be developed and validated for this specific application. Please let me know if you have any other questions!"
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "response": "Unfortunately the provided information does not clearly identify a cloud-based platform developed specifically for comparing GWAS. The text discusses utilizing supercomputing resources to apply complex statistical techniques to GWAS data, including a proof of concept test performed on a pseudo dataset. However, it does not name or describe a particular cloud platform designed for comparing GWAS studies. The key points made are:\n\n- Most published GWAS do not examine SNP interactions due to the high computational complexity. The goal is to use supercomputing to apply more complex statistics to uncover more genetic risk information.\n\n- A proof of concept Bayesian test was done on a pseudo GWAS dataset to demonstrate feasibility of performing exhaustive higher order analysis of GWAS using independence testing.\n\n- Strong scaling simulations showed the analysis could be accelerated from taking almost 2 weeks on 2 cores to under 10 minutes on 4096 cores.\n\nBut there is no mention of a specific cloud platform tailored for the purpose of comparing GWAS results across studies. The information focuses on utilizing high performance computing resources to enable more complex analysis of single GWAS datasets."
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "response": "Unfortunately, the document you provided does not contain any information about CMB305 or its potential use against sarcomas. The document discusses a phase 1 trial evaluating the safety and efficacy of a different compound called LY3039478, which is a selective Notch inhibitor. This trial was conducted in patients with soft tissue sarcoma (STS) and gastrointestinal stromal tumor (GIST). There is no mention of CMB305 anywhere in the document. \n\nBased on the information provided, I do not have enough details to determine if CMB305 could be used against sarcomas. The document focuses solely on evaluating LY3039478 and does not provide any relevant information to answer the question about CMB305. Additional documents discussing CMB305 itself would be needed to make an assessment about its potential efficacy against sarcomas. Without more context or background on what CMB305 is or how it works, I unfortunately cannot provide a substantive response about whether or not it could be used to treat sarcomas based on this document. Please let me know if you have any other questions!"
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "response": "Based on the information provided, some key points about manifestations of the Saint's triad are:\n\n1) It involves the concurrence of three conditions - cholelithiasis (gallstones), diverticulosis (pouches in the colon), and hiatal hernia. This combination of conditions was first described by C.F. Saint.\n\n2) Common symptoms that can manifest include abdominal pain, heartburn/reflux, nausea, constipation or diarrhea. These are due to the underlying conditions of gallstones, diverticulosis, and hiatal hernia. \n\n3) There may be complications from the individual conditions such as cholecystitis from gallstones, diverticulitis from diverticular disease, bowel obstructions, or gastrointestinal bleeding.\n\n4) The patient described in the excerpt has some features of Saint's triad (diverticulosis and two types of hernia) but the case study is more focused on the gastric and colon cancers discovered and the concept of paraneoplastic syndromes.\n\nIn summary, Saint's triad refers to the combination of gallbladder disease, diverticular disease, and hiatal hernia which can lead to shared gastrointestinal manifestations. The patient case has some overlapping conditions but involves additional medical issues beyond just Saint's triad."
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "response": "Unfortunately, the information provided does not specifically address whether overexpression of LY6K is associated with better prognosis for non-small cell lung cancer patients. The document discusses research examining the relationship between EZH2 overexpression and prognosis in NSCLC patients, but does not mention LY6K.\n\nThe document reports that EZH2 overexpression is associated with poor overall survival in NSCLC patients, especially among Asians, lung adenocarcinoma patients, and stage I NSCLC patients. But it does not give any information on LY6K or its potential association with prognosis. \n\nSo based on the information given, I cannot determine if LY6K overexpression is associated with better prognosis for non-small cell lung cancer patients. Additional research specifically examining LY6K would be needed to establish if there is an association and what the directionality of that association is. The document provided examines a different gene (EZH2) and does not directly address the question asked about LY6K."
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "response": "Based on the information in the document, it does not explicitly list specific CDK targets that are dephosphorylated during cytokinesis. However, it provides evidence that:\n\n1) The protein Iqg1, a component of the actomyosin ring, is a target of CDK (Cdc28-Clb) phosphorylation. \n\n2) Mutating CDK phosphorylation sites in Iqg1 to prevent its phosphorylation resulted in defects in cytokinesis, including delayed disassembly of the actomyosin ring. \n\nSo while specific targets are not listed, this suggests that dephosphorylation of Iqg1 may be important for disassembly of the actomyosin ring during cytokinesis. The document also indicates that phosphorylation of Iqg1 by CDKs regulates its interactions with other actomyosin ring components like Bni1 and Bnr1. So CDK targets involved in cytokinesis likely include Iqg1 and possibly other actomyosin ring proteins that associate with Iqg1. But an explicit list of targets is not provided."
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "response": "Unfortunately, there is no mention of \"Xanamem\" in the document provided. The document discusses the compounds Xiamycin A (XMA) and oxiamycin (OXM), which are bacterial indolosesquiterpenes produced by a marine Streptomyces species. \n\nIt describes their putative biosynthetic gene cluster xia and some of the genes involved in their biosynthesis, such as xiaK which encodes an aromatic ring hydroxylase and xiaI which encodes a flavin dependent oxygenase that converts indosespene to XMA. \n\nHowever, there is no reference to a compound called \"Xanamem\". Without any additional context or information provided, I do not have enough details to reasonably respond regarding what Xanamem is. The document focuses solely on the biosynthesis of XMA and OXM. Please provide more information if you have a specific question about Xanamem."
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "response": "Based on the document provided, it does not specifically mention the role of Hof1-Cyk3 interaction in yeast. The document describes a method to study protein-protein interactions involving protein phosphatase-1 and its regulatory subunits in yeast. Specifically:\n\n- They use a yeast conjugation assay to study interactions between a PP1 inhibitor protein and PP1 holoenzymes formed by fusion proteins that recruit endogenous yeast PP1 (called Glc7). \n\n- They introduce mutations in the VxF motif, which is important for direct binding of regulatory subunits to PP1. This allows them to distinguish direct vs indirect interactions.\n\nUnfortunately there is no information provided on Hof1 or Cyk3 proteins or their interaction. The document is focused on studying a different set of protein-protein interactions in yeast. Without any additional context or background on Hof1 and Cyk3, I do not have enough information to describe the role of their interaction in yeast based on this document. Please provide some additional background information or details if you would like me to elaborate further."
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "response": "Unfortunately, the provided passage does not mention anything about T-UCRs or their implication in gastric cancer. The passage discusses the role of UCH-L1 (Ubiquitin C-terminal hydrolase L1), a deubiquitinating enzyme, in gastric cardiac adenocarcinoma (GCA). Specifically, it states that:\n\n1) UCH-L1 expression is increased in GCA tumor samples compared to normal tissue. \n\n2) High UCH-L1 expression correlates with larger tumor size, higher TNM stage, lower cumulative survival, and worse prognosis in GCA patients.\n\n3) Silencing UCH-L1 expression in gastric cancer cells reduces their proliferation, colony formation, migration and invasion capacities. \n\nHowever, there is no information provided regarding transcription of ultraconserved regions (T-UCRs) or any link between T-UCRs and gastric cancer in this passage. The passage is solely focused on UCH-L1 expression and function in GCA. Therefore, unfortunately I do not have enough information to identify any specific T-UCRs implicated in gastric cancer based on this text. Please let me know if you have any other questions!"
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "response": "The Lupus Severity Index (LSI) is a tool developed by researchers to assess and quantify the severity and activity of systemic lupus erythematosus (SLE or lupus). Specifically, the LSI:\n\n- Was developed by the British Isles Lupus Assessment Group (BILAG) as a comprehensive way to measure lupus disease activity across different organ systems.\n\n- Looks at nine organ systems that can be affected by lupus, and categorizes each one as having no, mild, moderate, or severe disease activity based on various clinical and laboratory factors.\n\n- Provides both a global score that summarizes overall disease activity, as well as individual organ system scores.\n\n- Can track changes in lupus activity over time and with treatment. A higher score indicates more severe or active disease, while a lower score suggests the disease is more controlled.\n\n- Helps clinicians assess lupus severity, guide treatment approaches, and monitor patient progress.\n\nSo in summary, the Lupus Severity Index or LSI is a clinical tool specifically designed to quantify lupus activity and assist in managing this complex autoimmune disease. It was developed by lupus experts to measure the degree of flare in different body systems."
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "response": "Unfortunately the given passages do not mention ZSWIM6 or any disorders caused by de novo mutations in this gene. The passages discuss mutations in the Cu/Zn superoxide dismutase (SOD1), transactive response (TAR)-DNA binding protein (TARDBP) and fused in sarcoma (FUS) genes and their relation to amyotrophic lateral sclerosis (ALS). Specifically:\n\n- Mutations in SOD1, TARDBP, and FUS genes account for about 1/3 of familial ALS cases. \n\n- Mutations in these genes are also found in 1-2% of apparently sporadic ALS cases.\n\n- The passage presents a case of an ALS patient with a de novo missense mutation in the FUS gene. \n\n- This highlights the importance of screening both familial and sporadic ALS patients for FUS mutations.\n\n- It also suggests de novo mutations play a role in sporadic neurodegenerative diseases.\n\nBut there is no information provided about ZSWIM6 or disorders caused by mutations in this gene. The passages are focused on ALS and mutations in other specific genes like SOD1, TARDBP, and FUS."
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "response": "Unfortunately, the given text does not mention anything about Koos Classification or a disease that is classified using it. The text compares two grading systems - Konishi-Morson system (KMS) and Kozuka system - for grading dysplasia in colorectal adenomas. It does not provide any information about Koos Classification or a disease classified by it. The text focuses on analyzing the reproducibility of these two grading systems for adenomas and does not discuss any other disease classification system. Since the question specifically asks about Koos Classification, I do not have enough relevant information in the given text to answer which disease can be classified using it. The text compares two histological grading systems for colorectal adenomas and does not mention Koos Classification or any disease categorized by it."
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "response": "Unfortunately, the provided information does not specifically describe the in vivo effects of AZD8601. Document-0 discusses the pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886), which is a different compound than AZD8601. \n\nThe document details a study examining the effects of AZD6244 in mice models with human melanoma tumors. Key findings for AZD6244 include:\n\n- At clinically relevant exposures, AZD6244 effectively inhibits ERK phosphorylation and suppresses tumor proliferation in the mouse model.  \n\n- The study characterized the pharmacokinetic profile of AZD6244 in mice to design preclinical studies matching human exposure levels.  \n\n- A hysteretic relationship was described between AZD6244 pharmacokinetics and its pharmacodynamics related to target and pharmacologic response.\n\nHowever, without additional documents providing information, I do not have details on the specific in vivo effects of AZD8601 to provide in my response. Let me know if you have any other questions!"
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "response": "Based on the document, SAHFs (senescence associated heterochromatic foci) are formed in human diploid fibroblasts through the spatial repositioning and rearrangement of pre-existing heterochromatin into layered high-order chromatin structures (HOCS). Specifically:\n\n- SAHF formation involves the spatial clustering of chromatin with certain features, correlated with but not requiring the repressive histone marks H3K9me3 and H3K27me3.\n\n- These repressive histone marks are segregated from each other into layered HOCS within SAHFs during the dynamic changes as SAHFs form. \n\n- The linear epigenomic profiles/spreading of these repressive marks remains largely static, in contrast to what occurs during embryonic cell differentiation.\n\n- So SAHFs mainly form by repositioning and clustering pre-existing heterochromatin regions into layered HOCS, rather than by spreading of repressive chromatin marks to new regions.\n\nIn summary, the layered HOCS structure of SAHFs is achieved predominantly through the spatial reorganization and clustering of heterochromatin that is already present in human diploid fibroblasts."
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "response": "Unfortunately, the passage provided does not mention SATB1 or discuss its PDZ domain specifically. The passage talks about PDZ domains in general, providing background on how they mediate protein-protein interactions by recognizing certain sequence motifs. It then focuses on describing the Shank family of PDZ domain proteins and how they interact with the C terminus of the CL1 receptor.\n\nSince there is no information provided about SATB1 or what role its PDZ domain plays, I do not have enough context to provide a specific function. PDZ domains in general facilitate protein interactions and localization, but without more details on SATB1, I cannot give a satisfactory answer to the question asked about the function of its PDZ domain. I would need more information that mentions SATB1 and provides some background on what it does in the cell and how its PDZ domain contributes to that. Apologies that the information provided did not allow me to fully address the specific question asked. Let me know if you have or can provide any context about SATB1 that could help me formulate an appropriate response about the role of its PDZ domain."
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "response": "Based on the background provided, the basis of the BLISS technique is:\n\n1) It is a symbolic, graphical language that has been used with people with severe aphasia after stroke. Tony O'Donnell found an adapted version of BLISS meaningful for communication when spoken and written English was difficult after his stroke. \n\n2) The study aims to investigate if people without aphasia can match the adapted BLISS symbols to pictures without training, as well as explore the experiences of researchers with and without aphasia collaborating on research using experimental methods.\n\n3) The results showed that people without aphasia were able to match BLISS strings to pictures without training, though there was considerable individual variation. Additionally, the collaborative research process had many positive aspects and enabled contributions from researchers both with and without aphasia.\n\nIn summary, BLISS provides a graphical symbol system to facilitate communication in severe aphasia. This study explores an adapted version of BLISS and incorporates collaborative research with people with aphasia."
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "response": "Unfortunately I do not have enough information in the provided document to list three specific NK3R antagonists. While the document mentions NK receptors and NK-1 antagonists, it does not mention specific NK3R antagonists. If there is any other information you can provide related to naming three NK3R antagonists, please let me know and I would be happy to try responding again. Beyond that, I do not have personal knowledge to list three NK3R antagonists specifically. Please let me know if there is any other way I can assist!"
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "response": "Unfortunately, the given text does not clearly state which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects. The text discusses the ghrelin receptor GHS-R1a and its high constitutive activity, as well as experiments involving reconstituting a purified GHS-R1a monomer in a lipid disc to show that this high activity is an intrinsic property of the protein. However, it does not specifically mention any drugs or their profiling in human subjects related to the ghrelin receptor or inverse agonists. Based on the information provided, I do not have enough context to definitively state which drug was the first oral ghrelin receptor inverse agonist profiled in healthy subjects. Please provide more details if you would like me to make an attempt at answering the specific question asked."
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "response": "Unfortunately, the provided text does not contain information to directly answer the specific question about the protective efficacy of Vaxchora against moderate to severe cholera. The text discusses a study of the short-term effectiveness of the Shanchol oral cholera vaccine when used in response to a cholera outbreak in Guinea. It found that two doses of Shanchol was 86.6% effective against cholera in this specific context. However, there is no mention of the protective efficacy of Vaxchora or levels of cholera severity. Without this relevant information, I do not have enough context to provide a reasonable reply concerning the efficacy of Vaxchora against moderate to severe cholera specifically. I apologize that I do not have more pertinent information to answer this question. Let me know if you have any other questions!"
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "response": "Unfortunately, the given documents do not clearly state what the first cholera vaccine approved in the US was. Document 0 discusses a cholera vaccine candidate, CVD 103-HgR, that was developed by PaxVax and tested in a phase 1 clinical trial. It suggests this vaccine was undergoing renewed manufacture for potential future licensure in the US. However, it does not clearly state that this or any other specific vaccine was actually the first to be approved for use in the US. Without additional context or details on the history of US cholera vaccine approvals, I do not have enough information to definitively state what the first approved US cholera vaccine was based on the provided documents."
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "response": "Based on the information provided, the most common monogenic (single gene) cause of common variable immunodeficiency (CVID) identified in this study of Europeans is mutations in the LRBA gene. Specifically, the document states:\n\n\"Our results also identify five causative genetic variants in LRBA, CTLA4, NFKB1, and PIK3R1, as well as other very likely causative variants in PRKCD, MAPK8, or DOCK8 among others.\"\n\nAnd later estimates that 15-24% of the CVID cases analyzed have an underlying monogenic cause. Since LRBA mutations accounted for 5 of the identified causative variants, it seems to be the most common monogenic cause found in this cohort. Therefore, mutations in the LRBA gene are the most frequent single gene defect leading to CVID in the European patients analyzed in this study."
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "response": "Based on the information provided, it does not seem that the role of the IFIT1 gene is specifically discussed in relation to systemic lupus erythematosus (SLE). The passage discusses several factors associated with SLE, including:\n\n- Complement factor deficiencies in the classical activation pathway\n- A key role for IFN-alpha cytokine in SLE, with an activated IFN-alpha system being regularly observed in SLE patients \n- In lupus-susceptible, C4-deficient mice, lack of complement leads to elevated apoptotic DNA levels. This DNA accumulates in the spleen and induces IFN-alpha\n\nThe passage presents a unifying hypothesis for SLE induction involving complement deficiency and elevated IFN-alpha levels. However, it does not mention anything about the specific role or involvement of the IFIT1 gene in SLE. So based on the information provided, there does not seem to be any discussion of the role of IFIT1 in systemic lupus erythematosus. The focus is more on complement deficiencies, apoptotic DNA, and IFN-alpha induction."
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "response": "Based on the information in the document, the Liverpool Elbow Score is a patient reported outcome measure (PROM) that is used to assess the quality of healthcare delivery related to the elbow. Some key points about the use of the Liverpool Elbow Score from the document:\n\n1) It can be used to measure outcomes after elbow surgery - scores after surgery can be compared to a normal benchmark score to determine if the surgery improved outcomes. \n\n2) It provides a benchmark score for a normal population that can be used as a comparison. The study determined that the normal score is around 48 and is independent of factors like age, sex, and hand dominance.\n\n3) It is an elbow specific PROM focused on assessing elbow function and symptoms. Using an elbow specific PROM allows for a more targeted assessment.\n\n4) It can help assess the quality of elbow-related healthcare delivery by providing a standardized metric to compare outcomes. Better outcomes would be reflected in higher Liverpool Elbow Scores.\n\nIn summary, the Liverpool Elbow Score is an elbow specific outcomes measure used to evaluate elbow treatments and benchmark quality of elbow healthcare delivery. The study helps establish normal scores that can be used as a comparison for post-treatment outcomes."
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "response": "The 100,000 Genomes Project is an initiative focused on using whole genome sequencing to better understand the genetic basis of rare diseases and cancers. Some efforts related to sarcoma that have stemmed from this project include:\n\n- Sequencing sarcoma tumor samples and matching normal samples from consenting patients. This allows researchers to identify somatic mutations and genomic alterations that may be driving tumor growth and progression in sarcoma subtypes. \n\n- Integrating genomic data on sarcomas with clinical data to uncover correlations between certain mutations and treatment response or disease outcomes. This can shed light on prognostic markers and potentially actionable targets.\n\n- Comparing genomic profiles across sarcoma subtypes to understand similarities and differences in their molecular characteristics. This kind of analysis may lead to sarcoma subtype reclassification and more targeted treatment approaches.\n\n- Identifying novel gene fusions or other structural variants in sarcoma genomes through sequencing and analyzing how recurrent certain rearrangements are across cases. Some fusions are already defining characteristics and therapeutic targets in some subtypes.\n\n- Looking for patterns in sarcoma genomes relating to chromosomal instability or mutations in DNA repair genes that could represent new opportunities for therapies like PARP inhibitors that take advantage of DNA repair deficiencies. \n\nIn summary, the 100,000 Genomes Project is helping systematically characterize the genomic landscape of sarcomas to elucidate new prognostic markers, subtype classifications, and therapeutic targets. This knowledge aims to improve clinical management and outcomes for sarcoma patients."
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "response": "Yes, the document indicates that protein ALEX1 contains armadillo repeats. Specifically, it states that \"Arm protein lost in epithelial cancers, on chromosome X (ALEX; also known as armadillo repeat containing, X-linked [ARMCX]) is a novel subgroup within the armadillo (ARM) family, which has several ARM repeat domains.\" Since ALEX1 is part of the ARM protein family and this family contains armadillo repeat domains, this means ALEX1 contains armadillo repeats. So based on the information provided in the document, the answer is yes, ALEX1 does contain armadillo repeats."
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "response": "Based on the background information provided, some enzymes that remove histone modifications implicated in cancer and are potential targets for anti-cancer therapy in glioblastomas include:\n\n- Histone deacetylases (HDACs) - enzymes that remove acetyl groups from histones. Inhibitors like valproic acid (VPA) and trichostatin A (TSA) inhibit HDACs and increase histone acetylation.\n\n- Histone methyltransferases - enzymes that add methyl groups to histones. Chaetocin inhibits the histone H3 lysine 9 (H3K9) methyltransferase suv39h1. BIX01294 inhibits the H3K9 methyltransferase G9a. \n\n- Histone demethylases - enzymes that remove methyl groups from histones. 3DZNep inhibits the histone H3 lysine 27 (H3K27) demethylase UTX.\n\nIn summary, some key histone modification removing enzymes implicated in glioblastomas include HDACs, H3K9 methyltransferases (targeted by chaetocin and BIX01294), and the H3K27 demethylase UTX (targeted by 3DZNep). Inhibiting these enzymes leads to aberrant histone modifications and affects cancer cell viability."
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "response": "Based on the abstract provided, there is no evidence to support the claim that head CT scans increase the risk of brain tumors. The study examined the use of clinical criteria to predict whether patients with minor head trauma required a head CT scan. It did not evaluate whether the CT scans themselves increased the future risk of brain tumors. \n\nThe study found that using simple clinical criteria like severe headache, nausea, vomiting, and skull fracture allowed physicians to reduce the number of CT scans by 61% in minor head trauma patients, while still identifying all patients who required neurosurgery and most patients with abnormal CT findings. This suggests CT scans should still be used when clinically indicated, but more selective use based on risk factors can reduce costs and radiation exposure from unnecessary scans.\n\nThere is no data presented on brain tumor risk from CT scans. The study is focused on appropriate diagnostic use of CT for head trauma based on clinical predictors. To evaluate brain tumor risk, a different type of longitudinal study design would be needed that tracked cancer outcomes in patients receiving head CT scans over time. But this study does not provide evidence to support increased brain tumor risk from head CT imaging."
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "response": "Based on the passage, Otx2 is associated with primed pluripotency. The key evidence from the document supporting this is:\n\n\"Our genomic and biochemical analyses identified candidate mediators of primed state-specific Oct4 binding, including Otx2 and Zic2/3. Even when differentiation cues are blocked, premature Otx2 overexpression is sufficient to exit the naive state, induce transcription of a substantial subset of primed pluripotency-associated genes, and redirect Oct4 to previously inaccessible enhancer sites.\"\n\nSo the passage directly states that Otx2 is associated with primed state pluripotency, as opposed to naive pluripotency. It says that overexpressing Otx2 causes cells to exit the naive state and transition to a primed pluripotent state. Therefore, Otx2 is linked to and facilitates the establishment of primed pluripotency."
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "response": "Unfortunately, the given text does not clearly state the number of DNaseI hypersensitive sites that mark the murine beta globin locus region. Here is a summary of the relevant information:\n\n- The human beta globin LCR is defined by 4 erythroid-specific DNaseI hypersensitive sites (DHS/HSS) located upstream of the beta globin gene cluster\n\n- A 280bp fragment containing HSS4 of the human LCR is functional in murine erythroleukemia (MEL) cells and transgenic mice\n\n- This 280bp HSS4 fragment contains a number of DNaseI footprints that correspond to binding sites for GATA1, NF-E2 and other proteins\n\nHowever, there are no specific numbers given for DNaseI hypersensitive sites or DNaseI footprints in the murine beta globin locus. The text only discusses the properties of the human beta globin LCR and HSS4 region when tested in murine cells or mice. Without precise numbers stated for the murine beta globin locus itself, I cannot derive or provide a specific count. The provided text does not contain enough information to directly answer the exact number of DHS that mark the murine beta globin locus region. I apologize that I could not directly answer the question, but there does not seem to be a definite number stated in the text. Please let me know if you need any clarification or have an additional question."
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "response": "Unfortunately the document provided does not list any specific European influenza vaccines. It discusses the effectiveness of the 2017/18 influenza vaccines in Europe against different influenza strains, but does not provide any brand names or manufacturers of the vaccines used. \n\nThe document notes that in Europe in 2017/18, common influenza vaccines were trivalent, meaning they contained antigens for 3 different influenza strains - an A/H1N1 strain, an A/H3N2 strain, and one B strain (Yamagata lineage). It suggests getting the 2017/18 vaccine where influenza was still circulating.\n\nWithout more specifics on actual vaccine products used or approved for use in Europe, I am unable to provide a list of European influenza vaccine names or manufacturers. The information focuses more on analyzing vaccine effectiveness rather than listing the vaccine options available. Let me know if you need any clarification or have additional information that could help me provide a list of European influenza vaccine names."
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "response": "Based on the information provided, the Paramyxovirus genome is a negative-sense, non-segmented RNA. The passage states that the genome of the Fer-de-Lance virus (FDLV), which is a reptilian paramyxovirus, consists of \"seven nonoverlapping genes in the order 3' N-U-P-M-F-HN-L 5’\", indicating it is a single, continuous RNA strand that contains multiple genes. It also states the genome is 15,378 nucleotides in length. Furthermore, it refers to paramyxoviruses as single-stranded RNA viruses when it says \"pairwise comparisons of amino acid identities and phylogenetic analyses of all deduced FDLV protein sequences with homologous sequences from other Paramyxoviridae\". This suggests the genome is not segmented. \n\nThe passage also indicates the genome is negative-sense when it discusses \"transcription of the U gene\" and \"bicistronic N-U mRNA\". This shows the virus must first transcribe mRNA from its negative-sense genomic RNA before translation of proteins can occur. Therefore, based on the details provided, the Paramyxovirus genome consists of a non-segmented, negative-sense RNA."
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "response": "Based on the information provided, roflumilast cream would be effective for the treatment of chronic obstructive pulmonary disease (COPD). The key evidence supporting this includes:\n\n1) The document states that roflumilast is the first oral phosphodiesterase inhibitor indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and history of exacerbations. This suggests roflumilast is used to treat COPD.\n\n2) The document discusses improvements seen in clinical trials with roflumilast compared to placebo in measurements like forced expiratory volume and reductions in COPD exacerbations. This further indicates roflumilast's efficacy in treating COPD. \n\n3) While the document focuses on oral roflumilast specifically, it is likely a topical cream formulation containing roflumilast would also be used to treat COPD, though more studies may be needed to confirm the efficacy of this route of administration.\n\nIn summary, roflumilast cream would likely be effective for the treatment of chronic obstructive pulmonary disease or COPD based on the evidence for the oral form of roflumilast."
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "response": "Unfortunately the provided document does not contain information to directly answer the question on which tools have been specifically developed for identifying and visualizing ncRNA promoters. However, from the summary I can extract the following relevant points:\n\n1) CPSS 2.0 is an updated version of CPSS 1.0 for analyzing non-coding RNA (ncRNA) sequencing data. It includes features such as detection and profiling of various types of ncRNAs like lncRNAs and circRNAs.\n\n2) It has an enhanced visualization interface to show analysis results. However, it does not mention specifically visualizing ncRNA promoters.\n\n3) The contact given is for the CPSS tool developers, so they may be able to provide more details on if CPSS 2.0 includes any features/modules for identifying or visualizing ncRNA promoters.\n\nIn summary, the document discusses a bioinformatics pipelines for ncRNA analysis but does not provide direct information on tools for the specific task of ncRNA promoter identification and visualization that is asked in the question. The CPSS tool developers could be contacted for more details on its capabilities related to promoters. I could provide a more relevant response if additional documents or details on the analysis of interest are available."
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "response": "Based on the information provided, some example genes that the SWIM tool has identified as being down-regulated in glioblastoma include:\n\n- BACE1\n- KIF23 \n- WEE1\n- CDK2\n- PLP1\n- MBP\n\nThe document mentions that a total of 428 differentially expressed genes (DEGs) were identified between normal neural stem cells and glioma stem cells. Of those 428 DEGs, 331 were down-regulated and 97 were up-regulated. Some of the key down-regulated genes called out are KIF23, WEE1, and CDK2, which are associated with cell division. PLP1 and MBP were noted as being up-regulated genes related to myelination of neurons. So KIF23, WEE1, CDK2, PLP1 and MBP seem to be some example target genes identified by the SWIM tool that show differential regulation in glioblastoma vs normal cells."
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "response": "Unfortunately, the passage provided does not contain information about R packages developed for studying TADs (topologically associating domains). It discusses tricyclic antidepressants (TADs), which are a class of drugs used to treat depression. Specifically, it describes a procedure to analyze TAD drugs in patient serum using extraction columns and gas chromatography. It does not mention anything about R packages or topologically associating domains. Based on the information provided, I do not have enough context to provide an answer to the specific question asked about R packages developed for studying TADs. The passage is focused on a methodology for analyzing tricyclic antidepressants and does not discuss TADs as a biological concept or analytics related to studying them. I apologize that I cannot give a more relevant response since the passage contents do not align with the specifics of the question that was asked. Let me know if you need any clarification or have additional information to provide that could help address your actual question of interest."
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "response": "Unfortunately the text above does not provide information to directly answer which bioconductor tool has been developed for accessing bacterial regulatory networks. The text discusses using a microfluidic bioreactor to observe dynamics of E. coli carrying a synthetic population control circuit regulating cell density via quorum sensing. It does not mention any specific bioconductor tools. \n\nSince there is no relevant information in the text, I do not have enough context to provide a reasonable answer to the specific question asked about which bioconductor tool has been developed for this purpose. I would need more background information or details about bacterial regulatory networks and bioconductor tools to attempt to answer this accurately. Without any further context, I don't have sufficient knowledge to identify a reasonable answer. I apologize that I could not be more helpful in responding to this specific question. Please let me know if you can provide any additional information that could help guide a more useful response."
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "response": "Based on the information provided, the end products of the shikimate pathway are:\n\n1) Shikimate - The document mentions that shikimate is a key intermediate synthesized via the shikimate pathway. The engineered E. coli strain overproduces shikimate through this pathway.\n\n2) Neuraminidase inhibitors - The document states that shikimate is important for the synthesis of neuraminidase inhibitors. Though the specific inhibitors are not named, these would be further downstream products derived from shikimate.\n\n3) Related derivatives - The document also broadly mentions shikimate and related derivatives being produced through microbial production utilizing the shikimate pathway. However, the specific derivatives are not elaborated on.\n\nIn summary, the key end product is shikimate, which can then be used to synthesize neuraminidase inhibitors and other related derivatives. The engineered E. coli strain outlined produces shikimate in high quantities as an end product itself."
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "response": "Based on the information in the document, there is no clear evidence whether cabergoline is used for treatment of Nelson's syndrome specifically. The document discusses the use of cabergoline for treatment of Parkinson's disease, hyperprolactinemia, and acromegaly. It describes a case of a patient with acromegaly who developed valvular heart disease after taking low-dose cabergoline. The document does not mention the use of cabergoline for Nelson's syndrome. So from the information given, I cannot conclude whether cabergoline is used to treat Nelson's syndrome. Additional information would be needed to determine if cabergoline is part of the treatment regimen for Nelson's syndrome."
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "response": "Unfortunately, the passage does not mention Liebenberg syndrome or provide information to directly answer the question about its main manifestation. The text discusses Werner's syndrome, describing some of the common characteristics seen in 24 studied cases, such as short stature, early graying/hair loss, cataracts, and scleroderma-like signs. However, there is no information provided about Liebenberg syndrome specifically. Without any details on Liebenberg syndrome in the given information, I do not have enough context to provide an accurate answer on the main manifestation of that particular syndrome. The passage is focused solely on findings related to Werner's syndrome, so an answer about a different syndrome's manifestations cannot be reasonably inferred. I apologize that the information provided does not allow me to directly answer the question asked about Liebenberg syndrome's main manifestation. Let me know if you need any clarification or have additional information to share that could help provide context."
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "response": "Unfortunately, the provided information does not list any orally bioavailable MPS1 kinase inhibitors. The document discusses the development of dihydroquinazolinone inhibitors of p38alpha MAP kinase, which is a different kinase. There is no mention of MPS1 (monopolar spindle 1) kinase or any inhibitors targeting MPS1 kinase specifically. The passage talks about optimizing substituents on a p38 MAP kinase inhibitor scaffold to improve potency and oral bioavailability, but does not provide any information about orally bioavailable MPS1 inhibitors. To list orally bioavailable MPS1 inhibitors, I would need information specifically pertaining to inhibitors targeting MPS1 kinase and their oral bioavailability. Without such information, I do not have the details to provide a list of orally bioavailable MPS1 kinase inhibitors. Let me know if you need any clarification or have additional information to provide."
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "response": "Unfortunately there is no clear information provided in the passage stating that golimumab was specifically tested for diabetes. The passage discusses golimumab's approved use in treating rheumatological conditions and that it is a monoclonal antibody that targets tumor necrosis factor alpha. It also mentions its potential use for inflammatory bowel disease is still under evaluation. The passage then discusses a case where golimumab exacerbated ulcerative proctitis in a patient being treated for ankylosing spondylitis. But there is no mention of golimumab being tested for efficacy or safety in diabetes. Based on the information provided, there does not appear to be evidence showing golimumab was tested for diabetes specifically. The passage does not provide enough information to definitively state whether or not such testing occurred."
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "response": "Based on the information provided, progeria (Hutchinson-Gilford progeria syndrome or HGPS) is not caused by an autosomal recessive gene. Specifically:\n\n1) The passage states that mutations in the LMNA gene are responsible for HGPS. This implies a dominant mode of inheritance, as one mutated copy of the gene is sufficient to cause disease.\n\n2) Approximately 80% of HGPS cases are caused by a specific mutation - G608G - in the LMNA gene. This points to a dominant mutation being the primary cause, rather than autosomal recessive inheritance which would require two copies of a defective gene. \n\n3) There is no mention that both parents need to be carriers or that the disorder runs in families, which would support an autosomal recessive mode of inheritance. \n\n4) The evidence overall indicates that HGPS is caused primarily by a dominant mutation in the LMNA gene, likely G608G in most cases. There is no evidence presented to suggest it is an autosomal recessive disorder.\n\nIn summary, HGPS appears to exhibit autosomal dominant inheritance tied to mutations in LMNA, rather than being an autosomal recessive condition. The passage provides clear evidence to support this conclusion."
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "response": "Unfortunately, the question does not provide enough information for me to definitively state what the common variants at 12q14 and 12q24 are associated with. The text discusses research related to genetic variation at 8q24 and its association with prostate cancer risk in Korean men. It does not mention anything about 12q14 or 12q24 variants. \n\nWithout more context or details provided in the question, I cannot reliably comment on what 12q14 and 12q24 variants might be connected to. Additional information is needed to make an accurate assessment. The text discusses prostate cancer associations, but does not confirm if the 12q variants referred to in the question also relate to prostate cancer or some other disease/trait. More specifics would be helpful for me to write a thoughtful reply about what those particular variants are associated with. I'd be happy to revisit my response if the asker can provide some clarifying details."
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "response": "Based on the information provided, the ligands of the Roundabout (Robo) receptors are the Slit proteins. Specifically, the passage states that \"Drosophila Roundabout (Robo) is the founding member of a conserved family of repulsive axon guidance receptors that respond to secreted Slit proteins.\" Therefore, Slit proteins are ligands that bind to and activate the Robo receptors. The passage then goes on to discuss some of the intracellular signaling pathways and protein interactions that occur downstream of Slit-Robo binding, but it clearly identifies the Slit proteins as the ligands for the Robo receptors."
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "response": "Based on the information provided, there does appear to be a potential role for TFII-I in megakaryopoiesis (the production of megakaryocytes and platelets). A few key points:\n\n1. TFII-I is a multifunctional protein involved in both transcription and signal transduction, suggesting it could impact gene expression and cell signaling related to megakaryopoiesis. \n\n2. The document discusses alternatively spliced isoforms of TFII-I that form complexes in the nucleus and have the ability to bind DNA and transactivate reporter genes, indicating they are active as transcription factors. Transcription factors regulate megakaryopoietic gene expression.  \n\n3. The different isoforms work together to regulate target genes, and their co-expression leads to enhanced basal gene activity but attenuated signal responsive activity. This complex regulatory system could allow fine tuning of megakaryopoietic gene expression.\n\n4. The document does not directly examine the role of TFII-I in megakaryopoiesis. Further studies focused on the impact of TFII-I isoforms and complexes on megakaryocyte-specific gene expression would be needed to confirm if and how TFII-I contributes to this process. \n\nIn summary, the multifunctionality and gene regulatory properties of TFII-I isoforms suggest there could be a role in modulating megakaryopoietic gene transcription and signaling, but more direct evidence is still needed. I have provided an overall perspective on the potential involvement based on the background provided. Let me know if you have any other questions!"
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "response": "There is no information in the provided documents indicating whether atenolol is metabolized by CYP2D6. The passage discusses the metabolism of pilocarpine by plasma esterase to pilocarpic acid and by CYP2A6 to 3-hydroxypilocarpine. It also examines genetic polymorphisms in CYP2A6 that impact pilocarpine pharmacokinetics by affecting the conversion to 3-hydroxypilocarpine. However, there is no mention of atenolol or CYP2D6. Without further information, I cannot determine if atenolol is metabolized by CYP2D6 based on the information provided. The passage is focused specifically on pilocarpine metabolism and does not provide relevant information to answer the question about atenolol."
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "response": "Unfortunately I do not have enough context to provide a list of versions of ExpansionHunter based on the information given. The passage discusses PatternHunter II, which extends the spaced seed approach of the original PatternHunter program for faster homology search compared to Smith-Waterman alignment. However, there is no mention of ExpansionHunter or any indication of what versions may exist. Without more details on ExpansionHunter specifically, I am unable to generate a list of versions. Please provide more background information or details on ExpansionHunter if you would like me to attempt to list versions."
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "response": "Unfortunately the document provided does not mention the role of Adamts18 in hormone receptor signaling. The excerpt discusses Notch signaling and the proteases ADAM10 and ADAM17 acting on the Notch receptor to initiate release of the Notch intracellular domain (NICD) for downstream signal transduction. It does not reference Adamts18 or discuss any relationship to hormone receptor signaling pathways. \n\nSpecifically, the document outlines how ADAM10 is required for ligand-induced Notch1 signaling, while ADAM17 is involved in ligand-independent Notch1 signaling that can be dysregulated in leukemia. The proteases have differential roles depending on the context and activating conformational changes of Notch1. But again, there is no information provided relating Adamts18 to these Notch signaling pathways or any hormone receptor signaling cascades. Without further details on the interest in Adamts18, I unfortunately cannot provide insight into its specific role based on this excerpt. Please let me know if you have any other background information I could use to assist in addressing your question."
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "response": "Unfortunately, the provided document does not contain any information about the mode of action of Thiazovivin. The document describes a series of imidazo[2,1-b]thiadiazole and imidazo[2,1-b]thiazolesulfonamide carbonic anhydrase inhibitors and their anticonvulsant activities. It mentions one compound called 6-tert-butyl-2-sulfamoylimidazo[2,1-b]-1,3,4-thiadiazole (8, UK-15,454) and its effects on increasing cerebral blood flow and anticonvulsant activity, but does not provide any information about Thiazovivin or its mechanism of action.\n\nSince there is no context provided about what Thiazovivin is or what it is used for, I unfortunately do not have enough information to provide a reasonable answer or reply regarding its mode of action. Please provide some more background information or details about Thiazovivin and I would be happy to try to answer the question again. Let me know if you need any clarification or have additional information to share."
  }
]